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2. Abbreviations 
Array-CGH  Microarray-based comparative genomic hybridisation 
BAC Bacterial artificial chromosome 
CGH Comparative genomic hybridisation  
CNV Copy number variation, also known as polymorphism 
FISH Fluorescence in situ hybridisation 
G-banding G-bands in the chromosomes produced by the use of Giemsa stain 
HR-CGH High-resolution comparative genomic hybridisation 
IQ Intelligence quotient 
kb Kilo basepairs, 103 basepairs 
LCR Low copy repeat, also known as segmental duplication 
Mb Mega basepairs, 106 basepairs 
MLPA Multiplex ligation-dependent probe amplification 
OMIM Online Mendelian Inheritance in Man, database of genes and phenotypes 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim) 
PAC P1 derived artificial chromosome 
Oligo  Oligonucleotide 
SNP Single-nucleotide polymorphism 
UPD Uniparental disomy 
XLMR X-linked mental retardation 
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3. Summary 
A major cause of mental retardation is chromosomal abnormalities, but due to low sensitivity 
of conventional chromosomal karyotyping, these abnormalities may stay undetected, and the 
etiology of the impairment remains unknown. With the development of molecular cytogenetic 
methods, such as chromosome- and microarray-based comparative genomic hybridisation 
(HR-CGH and array-CGH), genome-wide detection of submicroscopic chromosomal 
abnormalities has become possible.  
 
To examine if implementation of such molecular cytogenetic methods would result in 
improved diagnostics of patients with mental retardation, we applied HR-CGH and array-
CGH on patients with mental retardation to investigate the diagnostic utility of the two 
methods. In addition, the phenotype-genotype correlations in the patients were examined. 
By HR-CGH analysis, we found that cryptic genomic imbalances could be detected in 
five out of 50 examined patients with mental retardation (10%), despite normal findings on 
conventional karyotyping. Four of the findings were de novo and interstitial. Based on a larger 
population of 554 patients, the HR-CGH detection rate of cryptic imbalances was 7,2%. Of 
note, 90% of the findings were de novo, and only 25% of the findings involved a subtelomeric 
rearrangement. Subsequent analysis of HR-CGH positive samples by 1 Mb array-CGH 
demonstrated, as expected, a highly improved mapping accuracy of the array-CGH method 
compared to the HR-CGH method. Application of 1 Mb array-CGH analysis on 20 selected 
patients with normal findings on both G-banded karyotyping and HR-CGH analysis gave an 
additional detection rate of 20%, suggesting a high diagnostic yield of the 1 Mb array-CGH 
method. Three out of the four findings were de novo and interstitial.  
The capacity for detecting chromosomal mosaicisms by the CGH methods (both  
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HR-CGH and array-CGH) was demonstrated by the unique finding of a mosaic combined 
tetraploidy for chromosomes 8 and 18 in a newborn with developmental delay, despite normal 
findings on G-banded karyotyping.  
The combination of several cytogenetic methods also made it possible to suggest 
candidate genes that might explain phenotypic features in two different families with mentally 
retarded individuals. In one family, a ~2,1 Mb sized deletion was located 1,6 Mb distal to a 
14q21.1q23.2 paracentric inversion. The deletion involved 16 genes. Among these, SPTB 
causing spherocytosis, and PLEKHG3, a guanide nucleotide exchange factor for Rho 
GTPases, and a candidate gene for causing the phenotype of mild mental retardation. In 
another family, an 8,9 Mb subterminal 19p13 duplication was detected in a 2 ½-year-old 
proband with severe mental retardation and extreme precocious puberty. Global gene 
expression analysis did not reveal candidate gene(s) for the hormonal disturbance. The 
proband´s mother was shown to have a between-arm insertion of the duplicated 19p13 
segment into 19q. The same balanced insertion was found in several other family members, 
including a maternally uncle who was also severely mentally retarded. Unexpectedly, a 3,9 
Mb 2q23.3q24.1-deletion was detected in him. The deletion contained seven annotated genes, 
and of these, FMNL2, a suggested regulator of Rho-GTPases, and NR4A2, an essential gene 
for differentiation of dopaminergic neurons, are possible candidate genes for causing the 
phenotype of severe mental retardation.  
 
In summary, we have demonstrated the usefulness of HR-CGH and array-CGH as diagnostic 
tools for patients with mental retardation and have provided detailed genotype-phenotype 
information on 89 patients. The work also adds knowledge for further understanding of minor 
or cryptic chromosome imbalances that cause varying degrees of mental impairment, 
malformations and/or dysmorphism.  
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4. Introduction 
Patients with mental retardation, defined by an intelligence quotient (IQ) below 70, represent 
a large group of the general population. It is estimated that the prevalence of children having 
mental retardation with or without dysmorphic features and/or malformations is 1-3% [1-4]. 
The overall incidence of mental impairment is found to be approximately 30% higher in 
males than females [5]. The underlying causes of mental retardation remain unidentified in 
many patients despite extensive investigation. It is estimated that the etiology of mental 
retardation is unknown in 30-50% of cases with moderate to severe mental retardation (IQ 
<50) and in 70-80% of cases with mild mental retardation (IQ 50-70) [6-8]. This can be a 
distressing and emotional situation both for the patient and the parents of an affected child, if 
an explanation or diagnosis and prognosis can not be given [9]. In addition, knowledge of the 
recurrence risk in a new pregnancy may also be an important aspect for the parents. If the 
phenotype-causing abnormality can not be detected then it can not be established if the 
unbalanced karyotype in the offspring is a de novo finding (i.e. not inherited from either 
parent) or a result of a parental carrier mechanism.  
Chromosomal abnormalities are a known cause of mental retardation (with or without 
dysmorphic features and/or malformations). It is estimated that chromosomal and genetic 
disorders account for 30–40% of cases with moderate to severe mental retardation, and for 
15% of cases with mild mental retardation [7]. Although a considerable number of cases with 
mental retardation can be explained by the presence of chromosome abnormalities detected by 
conventional karyotyping, a substantial part of the abnormalities in this patient group are 
undetectable or overlooked by this method due to limited resolution. Application of screening 
methods with a higher resolution is therefore needed in the diagnostic setting for an improved 
detection of submicroscopic abnormalities causing the developmental impairment. 
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The focus of this thesis has been the characterisation of chromosomal abnormalities in 
patients with mental retardation, with or without dysmorphic features and/or malformations, 
for obtaining more knowledge of the genotype-phenotype correlations in these patients. In the 
thesis we have examined the clinical usefulness of chromosome- and microarray-based 
comparative genomic hybridisation (HR-CGH and array-CGH) as screening methods for 
minor or cryptic chromosomal abnormalities (i.e. genomic imbalances) in these patients. In 
addition, the phenotypic outcome of deletions and duplications in the patients was explored.  
 
4.1.  Definition, classification and prevalence of         
mental retardation 
 
Definition of mental retardation 
As described by the World Health Organization (WHO), the American Association on 
Intellectual and Developmental Disabilities (AAIDD), and the American Psychiatric 
Association (APA), mental retardation is defined as a significant impairment of intellectual 
functioning and adaptive behaviour (i.e. the ability to function at age level in an ordinary 
environment measured by maturation level, learning skills, and social adjustment) with onset 
before age 18 years [10-12]. According to the WHO published international diagnostic system 
manual ICD-10 (International Statistical Classification of Diseases and Related Health 
Problems, 10th ed.) mental retardation is defined as: “a condition of arrested or incomplete 
development of the mind, which is especially characterized by impairment of skills 
manifested during the developmental period, skills which contribute to the overall level of  
intelligence, i.e. cognitive, language, motor, and social abilities.” [11]. 
Several other terms than “mental retardation” are today used for describing the condition 
of mental impairment. Among these are “developmental delay”, “delayed psychomotor 
 12
development” and “severe learning disability” which, in addition to the term “mental 
retardation”, have been used in the papers presented in this thesis. 
 
Classification of mental retardation 
Determination of the degree of mental subnormality is based on the score obtained on a 
standardised age-dependent intelligence test, such as the Wechsler Intelligence Scales. An 
intelligence quotient (IQ) below 70, which equals two standard deviations below the mean, is 
scored as a level of mental impairment [11,12]. In Table 1 is shown the different levels of 
mental retardation classified by the IQ-score, together with  the capacity of functioning, 
according to the international diagnostic system manual ICD-10 (Blocks F70-F73) [11].  
 
Table 1. Classification of mental retardation (MR) and capacity of functioning based on the 
intelligence quotient (IQ)-score according to ICD-10  
Level of MR IQ- score Capacity of functioning 
Mild 50 – 69 Likely to result in some learning difficulties in school. Many adults will be able to work and maintain good social relationships and 
contribute to society. 
Moderate 35 – 49 
Likely to result in marked developmental delays in childhood but most 
can learn to develop some degree of independence in self-care and 
acquire adequate communication and academic skills. Adults will need 
varying degrees of support to live and work in the community. 
Severe 20 - 34 Likely to result in continuous need of support. 
Profound < 20 Results in severe limitation in self-care, continence, communication and mobility. 
 
Most often the groups with an IQ lower than 50 are together referred to as “moderate to 
severe mental retardation” [6,8].  
 
Since intelligence is not a unitary characteristic, clinicians usually supplement IQ-tests with 
tests assessing the adaptive behaviour, such as the Vineland Adaptive Behavior Scales, for an 
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overall measurement of the degree of mental impairment. This is in agreement with the 
recommendations of APA given in their published manual for psychiatric disorders, DSM-IV 
(Diagnostic and Statistical Manual of Mental Disorders, 4th ed.), where the combination of an 
IQ below 70 together with significant limitations in two or more areas of adaptive behaviour 
(and onset before 18 years) is needed before a person is considered to have a mental 
impairment [10]. 
 
Prevalence of mental retardation 
Determination of the prevalence of mental retardation is a challenge and has been a matter of 
debate [2]. Non-ascertainment, especially of children having mild mental retardation (IQ: 50-
69) which can be difficult to recognize, complicates the determination. Children having 
moderate to severe mental retardation (IQ < 50) are easier recognizable since the mental 
impairment in this group most often is associated with dysmorphic features and/or 
malformations. After review of 39 prevalence studies on mental retardation in children, a 
prevalence of mental retardation on 3% was proposed, however, the reported rates varied 
greatly between the studies [2]. In prevalence studies made in the Scandinavian countries and 
in the United States, the prevalence of mental retardation in children was estimated to be 
around 1% [1,3,4]. Thus the reported prevalence of mental retardation in children seems to be 
1-3%. In this group moderate to severe mental retardation accounts for 0,3-0,5 % [2,13]. 
The etiology of mental retardation remains unknown in 30-50% of cases with moderate to 
severe mental retardation (IQ <50) and in 70-80% of cases with mild mental retardation (IQ 50-
70) [6-8]. 
 
4.2. Chromosomal abnormalities in mental retardation 
Chromosomal abnormalities causing an alteration of the normal dosage of genes may have  
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phenotypic consequences. Alteration of the dosage of developmental genes has been shown to 
be an important cause of mental retardation, and it is estimated that chromosomal and genetic 
disorders account for 30–40% of cases with moderate to severe mental retardation, but only 
for 15% of cases with mild mental retardation [7]. Most chromosomal abnormalities are 
produced by misrepair of broken chromosomes, by improper recombination or by 
malsegregation of chromosomes during mitosis or meiosis. A chromosomal abnormality may 
be present in all cells of the body (constitutional abnormality), or may be present in only 
certain cells or tissues (somatic abnormality, also called mosaic). Chromosomal 
abnormalities, whether constitutional or somatic, mostly fall into two categories: numerical 
and structural abnormalities, which will be described in more details in the sections below. An 
overview of some well-known chromosomal abnormalities associated with mental retardation 
is given in Table 2 (page 23). 
 
4.2.1.   Numerical abnormalities 
Aneuploidy, caused by loss or gain of individual chromosomes, can arise through two main 
mechanisms: Nondisjunction or anaphase lag. Nondisjunction is the failure of paired 
chromosomes to separate (disjoin) in anaphase of meiosis I, or failure of sister chromatids to 
disjoin at either meiosis II or at mitosis. Nondisjunction in meiosis produces gametes with 22 
or 24 chromosomes, which after fertilization by a normal gamete make a trisomic or 
monosomic zygote. Nondisjunction in mitosis produces a mosaic (see section 4.2.3.). 
Anaphase lag is the failure of a chromosome or chromatid to be incorporated into one of the 
daughter nuclei following cell division, as a result of delayed movement (lagging) during 
anaphase. Chromosomes that do not enter a daughter cell nucleus are lost.  
 
Autosomal abnormalities 
Autosomal monosomies and trisomies are usually embryonic or fetal lethal, with the  
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exception of trisomies for chromosomes 13 (Patau syndrome [14]), 18 (Edwards syndrome  
[15]), and 21 (Down syndrome [16]), which are observed in liveborn infants with an 
approximate frequency of 1:12000, 1:6000 and 1:750, respectively [17]. All the three types of 
trisomies result in mental impairment, but only trisomy 21 is compatible with long-term 
survival. Trisomy 21 (Down syndrome) is the most common single known cause of mental 
retardation and has the highest incidence at birth of any chromosome abnormality [18]. A 
karyotype of a patient with Down syndrome is shown in Figure 2 (page 25). It should be 
noted, that numeric autosomal abnormalities which are lethal in constitutional form may be 
compatible with life when in a mosaic state (see section 4.2.3.). 
 
Sex chromosome abnormalities 
Aneuploidy for sex chromosomes is more common in liveborns, and has a milder phenotypic 
consequence, than aneuploidy for any autosome. The four major sex chromosome 
abnormalities are: 45, X (Turner/Ullrich-Turner syndrome [19]), 47, XXY  
(Klinefelter syndrome [20]), 47, XXX (Triple X syndrome [21]), and 47, XYY (XYY 
syndrome [22]) and they are observed in liveborn infants with an approximate frequency of 
1:2700, 1:700. 1:800 and 1:700, respectively [17]. Individuals having these syndromes have a 
tendency towards learning disability and delayed speech and language skills, with the 
exception of individuals with Turner syndrome which usually show no mental impairment 
[17,18].  
 
4.2.2.   Structural abnormalities 
Structural chromosomal abnormalities are produced by misrepair of chromosome breaks or by 
recombination (crossover) between homologous - or nonhomologous chromosome- or 
chromatid segments in the meiotic or mitotic events. Strand exchange, so-called 
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recombination, can occur between nonhomologous chromosomal segments due to a high 
similarity in the DNA sequence, causing a “non-allelic homologous recombination”. 
Sequences with high similarity are frequently found across the human genome and are called 
low copy repeats (LCRs) or segmental duplications. Non-allelic homologous recombination 
can occur between homologous chromosomes, between sister chromatids, within the same 
chromosome arm, or between nonhomologous chromosomes. An unequal meiotic 
recombination event will produce unbalanced gametes which will result in an increased risk 
for an unbalanced progeny, as shown in Figure 1. Structural chromosomal abnormalities/ 
rearrangements are balanced if there is no net gain or loss of chromosomal material, and 
unbalanced if there is net gain or loss. 
 
    
bivalent at 
meiosis I
N           del          dup          N
gametes at meiosis II         
Fig. 1. The mechanism of recombination. Strand exchange can occur between nonhomologous 
chromosomal segments due to high similarity in the DNA sequence, they so-called segmental 
duplications or low copy repeats (shown as hatched boxes). A non-allelic homologous recombination 
event during meiosis will result in unbalanced gametes. In the figure the recombination occurs 
between homologous chromosomes producing two gametes with intrachromosomal abnormalities  
(del = deletion; dup = duplication; N = normal gamete).       
Illustration from Gardner and Sutherland [18]. 
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Balanced structural abnormalities 
Balanced abnormalities/rearrangements, as inversions, insertions and balanced translocations, 
are in general considered phenotypically neutral. However, in some cases a syndromic 
phenotype can occur if the chromosome break disrupts developmentally important gene(s), or 
the regulation factors of these. Also the position shift of a chromosome segment, a so-called 
position effect [23], may result in an altered regulation of gene expression causing abnormal 
development. Carriers of a balanced rearrangement have an increased risk of infertility, 
miscarriages and for having children with mental retardation and/or malformations due to the 
formation of unbalanced gametes.  
 
Unbalanced structural abnormalities 
Unbalanced structural abnormalities/rearrangements, such as deletions, duplications, 
unbalanced translocations, complex rearrangements, which cause gene dose alterations, are 
often observed in patients with mental retardation (see Table 2, page 23). The abnormalities 
can be either visible- or not visible by conventional microscopic chromosome analysis (see 
section 4.5.1.). Not visible abnormalities are called submicroscopic or cryptic. 
Submicroscopic structural abnormalities are a major cause of mental retardation/ 
abnormal development. A large fraction of these is microdeletion syndromes and 
microduplication syndromes with well characterised genotype-phenotype correlations. They 
are mostly caused by a non-allelic homologous recombination between LCRs/segmental 
duplications on homologous chromosomes during meiosis [24-26], as shown in Figure 1. 
Targeted analysis against genomic regions flanked by directly oriented LCRs have identified 
novel genomic disorders emphasising the role of LCRs as hotspots for chromosomal 
rearrangements [27,28]. The majority of the identified syndromes is microdeletion 
syndromes, possible due to a loss of gene-function most likely results in a more severe 
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phenotype, and also because microduplications are more technological difficult to detect than 
microdeletions (see sections 8.1.3. and 8.1.4.).  
Subtelomeric abnormalities, visible or submicroscopic, is another major group associated 
with mental impairment. They are often caused by recombination between nonhomologous 
chromosomes due to high similarity of repeat sequences located in the telomeres. 
Subtelomeric abnormalities are found in 5-7% of mentally retarded patients and it appears 
that the prevalence is higher in patients with a more severe mental retardation than in patients 
with mild mental retardation [6,29]. Individuals with subtelomeric abnormalities most often 
have dysmorphic features, growth retardation and congenital anomalies in addition to the 
mental impairment [30-32]. Also, families with subtelomeric abnormalities have a higher 
prevalence of mental impairment [29,32]. Since the telomeres are essential for the pairing of 
homologous chromosomes in meiosis and are critical for the complete replication of 
chromosome ends, it is not surprising that this type of abnormality has severe consequences. 
When combining 22 studies with a total of 2585 patients with mental retardation, it was found 
that approximately half of the subtelomeric abnormalities were caused by a de novo deletion, 
and about half by a balanced translocation segregating in a patient’s family [6]. 
Of all the chromosomes the X-chromosome is extra vulnerable for abnormalities, visible 
or submicroscopic, since this is the only chromosome which is expressed in a mono allelic 
manner in the cells. Because of this, a major cause of inherited mental retardation is due to X-
linked recessive impairment which is described in more detail in section 4.3.1. 
 
4.2.3.   Mosaicism 
Chromosomal mosaicism is defined as the presence of two or more populations of cells with 
different chromosomal content in one individual, which has developed from a single fertilized 
egg. The major mechanism for mosaicism is mitotic nondisjunction, but also postzygotic 
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anaphase lag in an initially chromosomally abnormal cell line will result in mosaicism. Many 
of the mitotically arisen aneuploidies lead to cell death, leaving no trace. But if viable, the 
earlier in embryogenesis that the mitotic error happens, the greater impact the diverging cell 
line will have on the phenotype. The phenotypic consequence depends on in which tissue the 
aneuploid cell line is located (e.g. in the brain) and how large a fraction the diverging cell line 
represents in the tissue. The mosaicism may be detectable only in blood cells or in fibroblasts 
(tissue cells). The distribution of chromosomal mosaicism in fibroblasts may show extreme 
karyotypic variation, also regionally [33]. Constitutional autosomal aneuploidies which nearly 
always are lethal may be viable when in a mosaic state. Some examples of this are 47,+8/46,N 
[34] and 47,+9/46,N [18]. In two studies including a total of 6185 patients with mental 
retardation, the detection of chromosomal mosaicism was 0,4% [35] and 0,5% [36].  
 
4.3.  Other genetic factors associated with                    
mental retardation 
4.3.1.   Monogenic disorders  
An altered function of a dosage sensitive single-gene which is important for brain function or 
development will result in mental impairment. Identification of monogenic causes of mental 
retardation through searches in the literature and in the Online Mendelian Inheritance in Man 
(OMIM) database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim) revealed 282 mental 
retardation genes involved in at least 1237 genetic disorders [37]. However, it is reasonable to 
speculate that the 282 genes represent a substantial underestimate of the correct number of 
mental retardation related genes, since variations of the terminology used (mental retardation, 
learning disability, cognitive impairment, developmental delay, etc) and of the clinical 
descriptions of the reported disorders limit such searches. 
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The majority of identified genes involved in mental retardation are located on the X-
chromosome. Even though the X-chromosome only contains ~4% of all human protein-
coding genes, 25,3% of all OMIM entries linked to mental retardation were mapped to the X-
chromosome (search done June 2006) [38]. Due to the mode of inheritance, recessive X-
linked mental retardation (XLMR) can affect several family members through multiple 
generations. Over 200 XLMR conditions involving 45 genes have been identified [39]. The 
most common is the Fragile X mental retardation syndrome caused by a mutation in the gene 
FMR1 [40], which is observed with an approximate frequency of 1:5000 and 1:8000 in males 
and females, respectively [41]. Since males only have one copy of the X-chromosome they 
are more vulnerable to mutations in the XLMR genes, and it is estimated that about 10% of all 
male mental retardation is caused by XLMR [42]. The overall incidence of mental impairment 
is approximately 30% higher in males than females [5], but it is still unknown whether or not 
all the difference in incidence can be explained by XLMR [42].  
Inborn metabolic monogenic disorders may cause mental retardation. The most known  
example is the autosomal recessive disorder phenyl-ketonuria (PKU/Følling's disease) which 
is caused by mutations in the gene PAH [43], resulting in a defective metabolism of 
phenylalanine. Untreated PKU will result in irreversible progressive mental impairment. 
Because of this, all newborns are today screened for PKU. The condition cannot be cured, but 
if early diagnosed and treated by a special diet the mental impairment can be avoided or 
limited. Some other examples of autosomal monogenic disorders associated with  mental 
retardation are: Smith-Magenis syndrome caused by mutation in the gene RAI1 [44,45]; the 
“9q34 subtelomeric deletion” syndrome caused by mutation in the gene EHMT1 [46]; and the 
Miller-Dieker syndrome caused by mutation in the gene LIS1 [47]. 
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4.3.2.   Genomic imprinting 
Genomic imprinting is a non-Mendelian mechanism of inheritance in which differences in 
gene function depend on whether the allele was inherited from the mother or the father. The 
effect of imprinting is a differential silencing and tight gene expression regulation of the 
genes located in the imprinted chromosome segment. It is estimated that ≤ 1% of the total 
human genes are regulated by this mechanism [48]. Many of the imprinted genes are 
expressed in the brain, and there is increasing evidence that these genes influence brain 
function and behaviour by affecting neurodevelopmental processes [48,49]. Imprinted genes 
or imprinted gene domains are vulnerable to mutations or abnormalities, as deletions or 
duplications, causing an altered gene expression. Also, even though the sequences of the 
genes are unaltered, a distribution of two imprinted alleles from the same parent (uniparental 
disomy; UPD) may have a phenotypic consequence due to the altered gene dosage. Six 
imprinting domains have been identified on the autosomes [50] and one well known is located 
on chromosome 15 at 15q11-q13. Depending on the parental origin of the affected alleles, 
deletions, mutations or UPD in this region will give rise to Prader-Willi syndrome if loss of 
expression of paternally imprinted genes or Angelman syndrome if loss of expression of 
maternally imprinted genes. Today, nine such non-Mendelian inheritance imprinting 
developmental syndromes have been identified [50]. Genetic marker analysis of the affected 
child and the parents can establish if an UPD is present. 
 
4.4.  Various etiological causes of mental retardation 
It is difficult to give an accurate estimate of the distribution of etiological causes of mental 
retardation or to give an estimation of the proportional contribution of cytogenetic 
abnormalities in mental retardation because reports vary in parameters such as clinical 
criterias of patient selection and of the examination methods used. But as an overview some 
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well-known chromosome abnormalities and syndromes associated with mental retardation are 
given in Table 2.  
 
 
Table 2. Selected well-known chromosomal abnormalities and syndromes associated with mental 
retardation  Table from Xu et al., [51]. 
  
 
 
Trisomy 21/Down syndrome  
Fragile X syndrome 
Unbalanced translocations 
Duplications 
Deletions (interstitial, terminal) 
Extra structurally abnormal chromosomes (markers) 
Diploid/triploid mosaicisma 
Submicroscopic aberrations at breakpoints in apparently balanced rearrangements 
Subtelomere rearrangements 
Cryptic deletions 
   del(1)(p36.3) Monosomy 1p 
   del(4)(p16) Wolf-Hirschhorn 
   del(5)(p15) Cri du chat 
   del(7)(q11.23q11.23) William syndrome 
   del(8)(q24.1q24.1) Langer-Giedion syndrome 
   del(11)(p13p13) WAGRb syndrome 
   del(15)(q11q13)pat Prader-Willi syndrome 
   del(15)(q11q13)mat Angelman syndrome 
   del(16)(p13.3) Rubinstein-Taybi syndrome 
   del(17)(p11.2p11.2) Smith-Magenis syndrome 
   del(17)(p13.3) Miller-Dieker syndrome 
   del(20)(p11.23p11.23) Alagille syndrome 
   del(22)(q11.2q11.2) VCFb/DiGeorge 
Uniparental disomy 
   UPD(14)mat IUGRb, developmental delay, precocious puberty, short 
stature, small hands and feet 
   UPD(14)pat Polyhydramnios, facial anomalies, severe neurologic 
involvement, skeletal anomalies and growth retardation 
   UPD(15)mat Prader-Willi syndrome 
   UPD(15)pat Angelman syndrome 
  
  aMost of the reported cases with a normal karyotype in blood but diploid/triploid   
   mosaicism in the cultured fibroblasts [van der Laar et al., 2002]. 
  bWAGR: Wilm's tumor, aniridia, genitourinary malformations and retardation of growth  
   and development; VCF: velocardiofacial; IUGR: intrauterine growth retardation. 
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4.5. Detection of chromosomal abnormalities and   
genomic imbalances 
Cytogenetic karyotyping aims at the identification of chromosomal abnormalities which can 
explain the phenotype, or specific phenotypic features, of the patient. In addition, the 
identification of a chromosomal aberration in specific patients has proven to be a successful 
way to identify the implicated genes and gain insight in the phenotypic consequences of a 
given gene malfunction. Several strategies can be used for examination of patients with 
mental retardation (with or without dysmorphic features and/or congenital abnormalities). The 
methods can either be directly targeted against regions or loci known to have phenotypic 
consequences or they can be genome-wide. In the sections below are described four widely 
used methods which all have been extensively used in the papers presented in this thesis. 
However it should be noted, that other methods like multiplex ligation-dependent probe 
amplification (MLPA)[52], and multiplex amplifiable probe hybridization (MAPH)[53], also 
have been proven to be useful for characterisation of patients with mental retardation [54-57]. 
 
4.5.1.  Conventional microscopic G-banded karyotyping 
Although already discovered in 1955 that normal human cells contained 46 chromosomes 
[58], identification of the individual chromosomes and chromosome bands was not possible 
until the development of chromosome banding techniques during the 1970s [59,60]. Since 
then, the most used method for chromosome analysis has been conventional microscopic 
karyotyping by G-banding. The method utilises the ability of Giemsa stain to bind differently 
to AT-basepairs versus GC-basepairs in DNA, and thereby constructing a dark and light 
chromosome band pattern which is distinctive for each chromosome. The resolution of the 
method, at a 400-550 band level in routinely prepared metaphases, is estimated to be 5-10 Mb 
depending on the density of the chromosome band pattern. A G-banded karyotype from a 
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patient with Down syndrome is shown in Figure 2. The method is especially useful for the 
detection of numerical chromosomal abnormalities or structural chromosomal abnormalities 
involving larger chromosomal segments, whereas smaller aberrations may be overlooked or 
are undetectable by the method. G-banded karyotyping has been applied in all the papers 
(papers I – V) presented in this thesis. 
 
 
Fig. 2. G-banded karyotype of trisomy 21 (Down syndrome). The presence of Down syndrome in a 
male was identified by an extra copy of chromosome 21 (47,XY,+21). 
Illustration by Helle Lybæk.     
 
4.5.2.  Fluorescence in situ hybridisation (FISH) 
Development of the fluorescence in situ hybridisation (FISH) method during the 1980s and 
1990s [61-66] made it possible to detect abnormalities which were undetectable (i.e. 
submicroscopic) or difficult to classify by G-banded karyotyping. The method utilises the 
ability of single-strand DNA to hybridise to complementary DNA sequences. When the DNA 
strands in the chromosome become separated, a targeted fluorescence-visible DNA sequence 
(also called probe) can hybridise onto them. Commercial available labelled probes targeted 
against specific loci (e.g. microdeletion syndrome probes), specific sequences (e.g.
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subtelomere probes), or chromosomes (e.g. paint or multicolour probes), have facilitated the 
detection of cryptic chromosomal rearrangements, and minor or submicroscopic 
abnormalities. In recent years, probes made from bacterial artificial chromosomes (BACs) or 
P1 derived artificial chromosomes (PACs) have become widely used, enabling FISH analysis 
at a higher resolution. The resolution of the method depends on the probe, FISH-technique 
and target DNA used, ranging from 3 Mb down to a few kilobases [67,68]. Some examples of 
different types of FISH-analysis are shown in Figure 3. The FISH-method has proven to be a 
powerful tool in clinical cytogenetics. However, the method has some major limitations:  
1) When analysing for submicroscopic abnormalities one must have a hypothesis about the 
possible affected region (e.g. based on the phenotype of the patient), since only one or a few 
loci can be investigated at the same time, and 2) When using multicolour FISH-probes for 
genome-wide analysis (as in multiplex FISH or spectral karyotyping (SKY)), flaring of 
fluorescence at the interface of translocated segments may lead to misinterpretation [69].  
The FISH method has been applied in all the papers (papers I-V) presented in this thesis. 
 
BAC-FISH
A
Subtelomere-FISH
B
Paint-FISH
C
 
Fig. 3. Examples of different types of FISH-analyses. A) BAC-FISH analysis detected a p21p21-
deletion on chromosome 3 (marked by an arrow); B) Subtelomere-FISH analysis detected a 
subtelomeric deletion of the q-subtelomere on chromosome 19 (marked by an arrow); C) Paint-FISH 
analysis of chromosome 4 (painted green) revealed a balanced translocation between chromosome 4 
and chromosome 6 (marked by arrows). 
Illustration by Helle Lybæk 
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4.5.3.  Chromosome-based high-resolution comparative genomic        
           hybridisation (HR-CGH) 
Development of the comparative genomic hybridisation (CGH) method during the early 
1990s made genome-wide screening for chromosomal imbalances possible without the need 
for living cells from the investigated patient [70]. In addition, only a small amount (≤1 µg) of 
patient sample is needed for the analysis. The method utilises competitive hybridisation of 
differentially fluorescence labelled patient DNA and normal reference DNA towards normal 
human metaphase chromosomes. Hybridisation of highly repetitive sequences is blocked by 
the addition of unlabeled Cot-1 DNA [61,63]. The ratio of fluorescence signal intensity of 
hybridised patient DNA versus reference DNA is calculated along the chromosomes and 
compared to a dynamic standard reference interval based on normal-to-normal hybridisations 
[71]. A deviation of the ratio-profile from the standard reference interval indicates a copy 
number change in the patient. The HR-CGH result is scored at a 99,5% confidence interval, 
and the location and size of a detected genomic imbalance is based on the position of the 
“imbalance-bar” on the respective chromosome ideogram generated by the analysis software. 
An outline of the HR-CGH method is shown in Figure 4 panel A. The resolution of the HR-
CGH method is 2-3 Mb for deletions [72,73], but is less sensitive for duplications. The HR-
CGH method has proven to be a powerful tool in clinical cytogenetics. The method has 
however a major limitation since only unbalanced chromosomal abnormalities (i.e. genomic 
imbalances) can be detected. Balanced structural chromosome aberrations, such as balanced 
reciprocal translocations or inversions, can not be detected as they do not change the DNA 
copy number. The HR-CGH method has been applied in all the papers (papers I-V) presented 
in this thesis. 
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Fig. 4. Outline of the CGH-methods: Chromosome-based high-resolution CGH (HR-CGH) in panel 
A, and microarray-based CGH (array-CGH) in panel B. Patient DNA (labelled green) and normal 
reference DNA (labelled red) is hybridised either onto chromosomes (HR-CGH) or onto immobilized 
DNA on a slide (array-CGH). Signals are detected using either a fluorescence microscope or a laser 
scanner and the ratio values between patient and reference are quantified and analysed with computer 
programs. An imbalance is detected as: A) A ratio plot (orange lines) deviation from the dynamic 
standard reference interval (black lines) in HR-CGH analysis, or B) A ratio plot (blue dots) deviation 
from the defined thresholds for normal DNA copy numbers (green lines) in array-CGH analysis. The 
same patient sample was analysed by both CGH methods, showing a duplication on chromosome 1 
(marked with green arrows) and a deletion on chromosome 5 (marked with red arrows).          
Illustration by Helle Lybæk. 
Patient DNA Normal reference DNA
Cot-1 DNA
A             B
 
4.5.4.  Microarray-based comparative genomic hybridisation (array-CGH) 
During the late 1990s, chromosome-based CGH was further developed into microarray-based 
CGH (array-CGH) [74-76]. The array-CGH method is based on the same principle of 
competitive hybridisation as chromosome-based CGH, but the targeted normal metaphase 
chromosomes have been substituted with normal DNA-sequences spotted onto a glass slide 
(also known as a microarray or shortly an array). When using arrays, the sensitivity of the 
method is no longer limited by the quality of the metaphase spreads, but by the size and 
density of the spotted genomic DNA-fragments, which improves the sensitivity of the CGH 
method significantly. An outline of the array-CGH method is shown in Figure 4 panel B. In 
array-CGH analysis, the ratio of fluorescence signal intensity of hybridised patient DNA 
versus reference DNA is calculated for each DNA fragment spotted on the array, and a ratio 
deviation from the defined thresholds for normal DNA copy numbers indicates a copy 
number change in the patient. The thresholds for normal DNA copy numbers can either be 
manually determined or determined by the analysis software algorithm. Information of the 
genomic location of the DNA fragments spotted onto the array can be found in genomic 
databases, as the Ensembl database (http://www.ensembl.org). Therefore, the size and 
location of an array-CGH detected genomic imbalance can be mapped by the genomic 
location of the detected DNA-fragment(s) showing a deviating signal intensity ratio. Different 
types of DNA can be spotted onto the array, as cDNA, PCR-products, genomic clone-insert 
DNA or oligos. The predominant type of array-platform has been arrays based on large-insert 
DNA from BAC or PAC clones, and arrays consisting of DNA from ~3500 BAC/PAC clones, 
enabling array-CGH analysis at an average resolution of 1 Mb, have become widely used for 
genome-wide screening of genomic imbalances [77-82]. An example of a 1 Mb array-CGH 
analysis detecting both a duplication and deletion on chromosome 7 is shown in Figure 5. 
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B dup
del
 
 
Fig. 5. Array-CGH analysis performed on a 1 Mb resolution BAC-array. The 1 Mb array-CGH 
profile of the patient sample is shown for all the chromosomes in panel A, and for chromosome 7 only 
in panel B. A deviation of the clone signal intensity ratios (blue dots) from the algorithm defined 
thresholds for normal DNA copy numbers (green lines) indicates a genomic imbalance. In the 
analysis, a sex mis-matched hybridisation between patient DNA (female) and reference DNA (male) 
was carried out, giving the expected deviation in clone signal intensity ratios on chromosome X and 
chromosome Y. A) Both a duplication (marked by a green arrow) and a duplication (marked by a red 
arrow) were detected on chromosome 7. B) The duplication segment (marked by “dup”) was mapped 
to 7q35q36.1 and the deletion segment (marked by “del”) to 7q36.2qter. 
Illustration by Helle Lybæk. 
 
Only genomic imbalances covered by the DNA-fragments spotted on the array can be 
detected by the array-CGH analysis. Therefore, the higher density of DNA-fragments spotted 
on the array, the higher sensitivity of the array-CGH method. As a consequence of this, high 
resolution BAC-arrays with overlapping BAC clones (so called tiling-arrays) have been 
developed for specific syndrome regions [83], for single chromosomes [38,84] or for genome- 
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wide coverage [85]. To further improve the sensitivity of the array-CGH method, arrays with 
oligonucleotide-fragments (so called oligos) being ~2500 times smaller than BAC DNA have 
been developed [86]. The accession and use of arrays have until recently been limited to non-
commercial “in house-made” arrays, but lately also a huge collection of commercial arrays 
have been available at a reasonable low cost. The commercial arrays are mainly oligo-arrays, 
but also “cytogenetic-focused” BAC-arrays targeted against regions associated with 
constitutional genetic disorders are available. Also oligo-arrays based on single-nucleotide 
polymorphisms (SNPs) are commercial available, enabling both allelotyping (i.e. the ability to 
detect uniparental disomies) and examination for DNA copy numbers in the same analysis. 
Oligo-arrays facilitate genome-wide array-CGH analysis at a much higher resolution than 
BAC-arrays [87]. At the moment (September 2008) an array-CGH resolution as high as ~6 kb 
is possible by the use of commercial available oligo-arrays. The improved detection capacity 
of the array-CGH method towards submicroscopic abnormalities (i.e. genomic imbalances) 
indicates that the method in the future will be an important tool in clinical cytogenetics. But it 
should be noted that, as for the HR-CGH method, only unbalanced chromosome 
abnormalities changing the DNA copy number can be detected by the array-CGH method. 
The array-CGH method has been applied in four of the papers (papers II-V) presented in this 
thesis. 
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5. Aims of the study 
The overall aim of this study was to screen for chromosomal imbalances and obtain more 
knowledge of the genotype-phenotype correlations in patients with varying degrees of mental 
retardation with or without dysmorphism and/or malformations. The study has focused on the 
following topics:    
 
1) Evaluation of chromosome- and microarray-based comparative genomic hybridisation 
(HR-CGH and array-CGH) as diagnostic screening methods for detecting minor or 
cryptic chromosomal imbalances in patients with mental retardation.  
 
2) Exploration of the phenotypic outcome of deletions and duplications in patients with 
mental retardation in order to obtain genotype-phenotype information. 
 
3) Detection of occult chromosomal mosaicisms in patients with abnormal development. 
 
4) Evaluation of candidate genes that might explain phenotypic features in families with 
mentally retarded individuals. 
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7. Summary of results 
Paper I 
In this study we investigated the usefulness of the HR-CGH method for the detection and 
characterisation of minor or cryptic chromosomal imbalances. A total of 66 patients with 
mental retardation and most also having dysmorphic features and/or malformations were 
examined. After conventional G-banded karyotyping, blood samples were selected for HR-
CGH analysis, either because the observed chromosomal abnormality was small and doubtful 
or difficult to classify (16 patients), or because clinical features were suggestive of a 
chromosomal abnormality but the karyotype was found normal by G-banding (50 patients). In 
the first group, HR-CGH identified the origin of additional chromosome material in nine 
patients, of which two patients had marker chromosomes in mosaicism. In addition, an 
apparently balanced de novo translocation was in one patient identified to be unbalanced. In 
the last group, HR-CGH detected a chromosomal imbalance in five patients, of which four 
patients had an intrachromosomal imbalance, giving a detection rate of 10% in patients 
having an apparently normal karyotype.  
 
Paper II  
As an extension of the study described in paper I, and for more precise phenotype-genotype 
information, we applied 1 Mb resolution array-CGH for investigation of all HR-CGH findings 
done in our diagnostic laboratory during a 6-year period. A total of 590 patients, all except 
three being mentally retarded, and most also having dysmorphic features and/or 
malformations, had been examined by HR-CGH analysis. Of these, 36 patients had minor but 
visible findings on G-banded karyotyping, whereas 554 patients had normal finding on G-
banded karyotyping. In the last group, a genomic imbalance was detected by HR-CGH in 40 
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patients (7,2%): 29 deletions, 3 duplications, 4 unbalanced translocations, and 4 occult 
trisomy mosaicisms. When genomic BAC-arrays became available from the Norwegian 
Microarray Consortium, 1 Mb array-CGH was applied on all HR-CGH positive samples for 
more precise mapping, and thus more accurate phenotype-genotype information. To examine 
the diagnostic sensitivity of 1 Mb array-CGH in the remaining 514 patients with normal 
findings on both G-banded karyotyping and HR-CGH analysis, a subset of 20 patients with 
particularly high suspicion of having a chromosomal imbalance as the cause of abnormal 
development was selected. In four of the patients (20%) an imbalance was detected: three 
deletions and one duplication. Of note, 73 out of the 80 array-CGH mapped patients had a de 
novo finding (91%). Taken together, the work provided detailed phenotype-genotype 
information on 80 patients with minor and cryptic chromosomal imbalances. 
 
Paper III  
In this study, a familial 14q21.1q23.2-inversion that co-segregated with spherocytosis and 
severe learning difficulties or mild mental retardation was investigated by BAC-FISH and 
oligo-based array-CGH. As expected, a deletion of the beta-spectrin gene SPTB, a known 
cause of spherocytosis, was found. More unexpectedly, this deletion was ~1.6 Mb distal to the 
14q23.2 inversion breakpoint. The deletion spanned ~2.1 Mb and contained 15 annotated 
genes in addition to SPTB, among them PLEKHG3, a guanide nucleotide exchange factor for 
Rho GTPases. PLEKHG3 is highly expressed in the brain and our best candidate gene for 
causing the mild mental retardation.  
 
Paper IV  
In this study, the cause of marked dysmorphic features, malformations and developmental 
delay in a newborn was examined. G-banded karyotyping gave normal findings, whereas a 
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50% DNA increase of both chromosome 8 and 18 was detected in the patient by HR-CGH 
and 1 Mb resolution array-CGH. Most unexpectedly, FISH analyses of meta- and interphases 
identified the DNA increase to be caused by a mosaic combined tetrasomy of chromosomes 8 
and 18. Allele analyses showed an equal allele distribution from the parents, showing that the 
double tetrasomy was a result of mitotic malsegregation of all four chromatids of both 
chromosome pairs. At age 20 months, double tetrasomic leukocytes could no longer be 
detected by CGH in the child. Pairing of homolog chromosomes is occasionally observed in 
metaphase spreads from fetal cell cultures. That such pairing may have a function is indirectly 
suggested by our findings in the patient. We suggested that the possible origin of the double 
tetrasomy is incomplete correction of a tetraploid state resulting from failed cytokinesis or 
mitotic slippage during early embryonic development. If so, this suggests that normal cells 
may have a mechanism for tetraploidy correction that involves pairing of homolog 
chromosomes that could be important for genomic maintenance. 
 
Paper V  
In this study, the cause of puberty onset before age 5 months, short stature, hand anomalies 
and severe mental retardation in a 2 ½ year old girl was examined. Normal findings were 
made on G-banded karyotyping and HR-CGH analysis, whereas an 8,9 Mb subterminal 19p13 
duplication containing 215 predicted genes was detected by 1 Mb array-CGH analysis. It was 
initially assumed that the duplication contained the kisspeptin receptor gene GPR54, known 
to stimulate induction of puberty, but more refined duplication mapping by high-resolution 
oligo array-CGH excluded this possibility. In an attempt to understand the genotype-
phenotype correlation, global gene expression was measured in skin fibroblasts. The overall 
gene expression pattern was quite similar to controls, and only about 25% of the duplicated 
genes had an expression level that was increased by more than 1,3-fold, with no obvious 
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changes that could explain the extreme precocious puberty. G-banded karyotyping of the 
proband´s mother showed a balanced between-arm insertion of the duplicated segment that 
resembled a pericentric inversion. The same balanced insertion was found in several other 
family members, including one who had lost a daughter with severe mental retardation and 
menarche at age 10. Another insertion carrier was severely mentally retarded and short 
statured, but not dysmorphic. His phenotype was initially ascribed to a presumed cryptic 
chromosome 19 imbalance caused by the 19p-into19q insertion, but subsequent array-CGH 
detected a 3,9 Mb deletion of 2q23.3-2q24.1. This novel microdeletion involved seven genes, 
of which, FMNL2, a suggested regulator of Rho-GTPases, and NR4A2, an essential gene for 
differentiation of dopaminergic neurons, may be critical genes for the proposed 2q23q24 
microdeletion syndrome. 
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8. Discussion 
8.1. Methodological considerations 
8.1.1.  G-banded karyotyping  
In the study, we have used the G-banding method for initial screening of chromosomal 
abnormalities. This method is a very useful tool but has some limitations one should bear in 
mind when interpreting the result. First, the resolution of the method depends on the quality 
of the metaphase spreads and the density of the chromosome bands. Despite continous efforts 
to achieve the best possible chromosome quality for the analysis, we sometimes observed 
reduced quality of the chromosomes in patient samples, resulting in a lowered resolution. 
Also, chromosomal rearrangements between segments with similar chromosome band pattern 
or chromosomal abnormalities in regions with a low chromosome band density may remain 
undetected although the size of the imbalance is above the usual resolution of the G-banding 
method. Finally, phytohemagglutinin (PHA)-stimulation during culturing of blood leukocytes 
may favour growth of normal cells, leading to a selection against cells bearing (growth 
limiting) imbalances. This phenomenon has previously been described  for patients having 
chromosomal abnormalities in mosaicism [35,77]. Thus the harvested cells may not always 
represent the “true chromosomal content” in the patient. Because of the issues described 
above, patients having normal findings on G-banded karyotyping were, if recommended by 
experienced clinicians at our department, followed up by FISH, HR-CGH, or recently, array-
CGH analysis, for further examination. 
 
8.1.2.  FISH 
We have used the FISH method for targeted chromosomal examination or for verification of 
results obtained by other methods. The FISH method enables high-resolution analysis but has 
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some possible short comings which may lead to a false result. As described above, obtaining 
good quality chromosomes from a patient sample can be a challenge. Limited probe 
resolution may also bias the result. This is especially relevant when analysing for 
intrachromosomal duplications since two closely located FISH signals may be overlapping or 
can not be distinguished in the fluorescence microscope, resulting in a false-negative result. 
Because of this, repeated HR-CGH analysis was done if an initially HR-CGH-detected cryptic 
duplication could not be verified by FISH analysis. More recently, we have applied oligo 
array-CGH for detection and verification of cryptic duplications. Finally, when using 
BAC/PAC clones as probes, it should be kept in mind that the information of the genomic 
clone location reported in the databases may be incorrect. As a consequence of this, we have, 
if available in the examined region, used verified sequenced BAC clones in the FISH-
analyses. 
 
8.1.3. HR-CGH 
In the initial period of this study, we used HR-CGH for more extensive genome-wide 
screening of genomic imbalances. The method enables screening at a higher resolution than 
the G-banding method, but has some limitations or possible biases, which one should bear in 
mind. As for the methods above, the output of an HR-CGH analysis is highly dependable on 
the chromosome quality. Because of this, chromosomes from the same normal donor were 
used in the analyses. Furthermore, slides with the metaphase spreads were produced in large 
batches and each slide was manually checked in a light microscope for ensuring a similar and 
good chromosome quality. When using HR-CGH analysis it should be kept in mind, that a 
normal finding only shows that the DNA copy number in the karyotype is balanced and not 
that the karyotype is normal. Therefore, the HR-CGH method has in the study been used in 
combination with the G-banding method for visualisation of the patients´ chromosomes. To 
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reduce the level of possible false-positive HR-CGH findings, imbalances were scored as a 
deviation from the standard reference interval of CGH ratio profiles at 99,5% confidence 
intervals [71]. However, small imbalances or imbalances in mosaicism may only be visible at 
lower confidence intervals (e.g. 95% or 99%), therefore these intervals were also inspected 
for interpretation of the result. It should also be noticed that duplications are more difficult to 
detect than deletions by HR-CGH analysis, since duplications “only” cause a 50% change in 
patient DNA content compared to the normal DNA ratio (ratio of 3/2) while deletions lead to 
a 100% change in DNA content (ratio of 1/2). Therefore, the risk for false-negative findings 
by this method is higher for duplications than deletions, especially when the imbalances are 
small. In mosaicism, the CGH-detected (both HR-CGH and array-CGH) level of change in 
patient DNA content may represent an even higher level of DNA change in the affected cells. 
Therefore, and because the patient chromosomes are not visible by the HR-CGH method, all 
HR-CGH findings were re-examined by G-banded karyotyping on high quality chromosomes 
(band level above 600), by BAC-FISH analysis, or recently by array-CGH analysis, for 
examination of the cause for the detected change in patient DNA content and for verification 
of the HR-CGH finding.  
 
8.1.4.  Array-CGH 
More recently, we have introduced array-CGH as a new method for genome-wide 
examination of genomic imbalances. The method enables screening at a higher resolution 
than the HR-CGH method, although with some limitations or possible biases. First, the 
quality of an array-CGH analysis is highly dependable on the performance of the array used. 
The majority of the array-CGH analyses described in this thesis were done on 1 Mb BAC-
arrays which were produced in-house by the Norwegian Microarray Consortium. For 
achieving best possible quality, arrays were printed in batches of 25 slides, and at least one 
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array from the batch was test hybridised before the array-batch was “released” for further use. 
For ensuring comparable quality of the array-CGH analyses from batch to batch, each new 
batch was always tested on two samples with known minor imbalances and on a normal-to-
normal hybridisation. If these control assays were not satisfactory, the array batch was not 
further used. For reduction of the background noise (i.e. noise-to-signal ratio) in the array-
CGH analyses, only Cot-1 DNA batches which had been thoroughly tested in several normal-
to-normal hybridisations, showing a satisfying blocking ability of repetitive sequences, were 
used in the array-CGH experiments. To reduce the detection of normally occuring copy 
number variations (CNVs) (see section 8.3.), a commercial reference DNA consisting of a 
pool of 10 normal individuals (either females or males) was used in the analysis. As for HR-
CGH, a normal finding by array-CGH only shows that the DNA copy number in the 
karyotype is balanced and not that the karyotype is normal. Also, only imbalances covered by 
the array-spotted DNA-sequences can be detected by the method. This is particular a problem 
when using “low-resolution” arrays like the 1 Mb BAC-array. Commercial high-resolution 
oligo-arrays, which have been used in papers III and V in this thesis, have smaller “inter-
sequence-gaps”, enabling array-CGH analysis down to a resolution of ~6kb. However, the 
shorter oligo-sequences (25-mer or 60-mer) compared to the larger size of BAC DNA (~150 
kb), make the oligo-arrays more vulnerable for unspecific hybridisation causing a higher level 
of background noise. Also the commercial oligo-arrays do not have oligo-duplicates present 
in the array, whereas in the BAC-arrays, which we have used for 1 Mb array-CGH analyses, 
each BAC DNA is spotted four times on the array, making the array-CGH data more robust. 
Thus both types of arrays have their forces and limitations, which should be borne in mind. In 
the array-CGH analyses, or DNA copy number analyses if a SNP-based oligo-array has been 
used, we have used the analysis software and available algorithms as recommended by the 
respective supplier. It should be noted, that the array-CGH threshold algorithms favour 
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detection of deletions compared to duplications since the threshold cut offs for both deletions 
and duplications are determined at an equal distance from the mean of all intensity ratios. As 
the intensity ratios for deletions are more distant from the mean (ratio of 1/2: log2 = -1,0) 
compared to the intensity ratios for duplications (ratio of 3/2: log2 = 0,59), there is a higher 
risk that some duplications may be missed. For visualisation of the patients´ chromosomes, 
array-CGH analysis was always used in combination with G-banded karyotyping. Array-CGH 
findings were verified by re-examination of G-banded high quality chromosomes (band level 
above 600), by BAC-FISH analysis, or by array-CGH analysis on another type of array. 
 
8.1.5.  Microarray-based gene expression analysis 
In one of the papers, we have used microarray-based gene expression analysis for global 
profiling of the transcriptome of patient fibroblasts compared to fibroblast from control 
persons. A commercial single-channel oligo array-platform was used in the analyses. It is 
important to note that genes expressed in the brain causing a certain phenotype of mental 
impairment, may not be expressed in the examined fibroblasts, and vice versa, genes 
expressed in the examined fibroblasts may not be active in the brain. Also, the use of 
expression data from a single patient calls for cautious procedures. We therefore only 
included genes with a high signal-to-noise ratio to filter out most genes with unreliable 
expression levels. Since no obvious candidate genes were identified in the analyses, real-time 
PCR verification and validation of single-genes was not performed. 
 
8.2. Clinical usefulness of HR-CGH and array-CGH 
As discussed in the Introduction, the etiology remains unknown for the majority of patients 
with mental retardation. This situation can be explained in part by the limited resolution of the 
chromosomal analysis methods previously used for routine examination of these patients. The 
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development of molecular cytogenetic methods, as HR-CGH and array-CGH, has enabled 
chromosomal analysis at a higher resolution than the traditional cytogenetic method. For this 
reason, we have in this thesis examined the clinical usefulness of HR-CGH and array-CGH, 
for the detection and characterisation of minor and cryptic chromosomal imbalances in 
patients with mental retardation. In addition, we have explored the phenotypic outcome of the 
CGH-detected duplications and deletions to obtain phenotype-genotype information of 
patients with varying degrees of mental impairment, malformations and dysmorphism. 
 
This thesis also illustrates the impressive development that the CGH method has undergone 
during the last decade. Firstly, the implementation of microarray technology has made 
genomic screening at a resolution below 3 Mb possible. Moreover, the recent developments 
of high density oligo-arrays have tremendously increased the sensitivity of the array-CGH 
method and made detection of genomic imbalances down to a size of few kilobases possible. 
The years to come will show the limit in diagnosic resolution of the array-CGH method when 
examining patients with mental retardation. 
 
8.2.1.  Detection of cryptic imbalances by HR-CGH (papers I and II) 
In patients with mental retardation and/or dysmorphic features and malformations, an 
unbalanced karyotype can be found by G-banded karyotyping in 10% [88] to 16% [8] of the 
individuals. In patients having normal G-banded karyotypes, subtelomeric aberrations can be 
detected in 5-7% of the individuals by subtelomere FISH-screening [31,62,89,90]. As 
described in the Introduction, the prevalence of subtelomeric abnormalities appears to be 
higher in patients with a more severe mental retardation than in patients with mild mental 
retardation [6,29], and addition, families with subtelomeric abnormalities have a higher 
prevalence of mental impairment [29,32]. Subtelomere FISH-screening has been an important 
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diagnostic tool for examination of patients with mental retardation, however, cryptic 
interstitial abnormalities remain undetected by this method. Because of this, we decided to 
examine the capacity of the HR-CGH method for the genome-wide detection of cryptic 
chromosomal imbalances -both interstitial and subtelomeric- in patients with mental 
retardation. A summary of the results presented in papers I and II is shown in Table 3. 
 
Table 3. Detection of cryptic chromosomal imbalances in patients with mental retardation by 
HR-CGH analysis   All patients (cases) had normal findings on G-banded karyotyping. 
Abnormal findings 
Study Number of cases 
Total number (%) Interstitial imbal. de novo events 
Paper I 50 5 (10,0) 4 4 
Paper II 554 40 (7,2) 30a 36 
aBased on fine-mapping results by 1 Mb array-CGH analysis. 
 
Based on 50 patients, the HR-CGH detection rate of chromosomal imbalances was 10% in 
patients having an apparently normal karyotype (Table 3, paper I). Of note, four of the 
patients had an interstitial abnormality and the majority of the HR-CGH findings were de 
novo (Table 3). Thus, our findings showed that the HR-CGH method was very useful for 
identification of novel cryptic abnormalities which are undetectable by G-banding and FISH 
subtelomere-screening. In addition, based on 16 patients, the method was found useful for 
additional characterisation of visible findings which were difficult to classify based on the G-
banding result (paper I).  
 
Based on these findings, the HR-CGH method was implemented in our cytogenetic diagnostic 
laboratory for examination of selected patients with mental retardation. Paper II summarises 
the HR-CGH detections made in these patients during a 6-year-period. A total of 590 subjects 
had been examined (all except three being mentally retarded), of which 554 patients had 
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normal findings on G-banded karyotyping. In this larger sample, the HR-CGH detection rate 
of cryptic imbalances was 7,2% (Table 3). Others studies have reported a HR-CGH detection 
rate of 10% and 12% based on 144 and 424 patients, respectively [91,92]. The lower detection 
rate in our study may be due to different criteria of patient selection for HR-CGH analysis. Of 
note, 90% of the patients had a de novo finding, and only 25% of the findings involved a 
subtelomeric rearrangement (Table 3). HR-CGH analysis was also applied on 36 patients 
having a minor but visible finding on G-banded karyotyping for more precise characterisation 
(paper II). 94% of these patients had a de novo finding. 
HR-CGH findings were made in 76 patients, and, except for the Y-chromosome, genomic 
imbalances were found on all chromosomes. The highest numbers of aberrations, with 
deletions being as common as duplications, were seen on chromosomes 7 and 8. On 
chromosome 19, our most gene-dense chromosome, only duplications were observed. 
Another interesting observation was that in the group of 40 patients having cryptic 
abnormalities (i.e. normal G-banded karyotypes), deletions were ten times more common than 
duplications, and the six non-mosaic patients known to have severe mental retardation all had 
deletions. In contrast, in the group of 36 patients having minor but visible abnormalities, 
deletions- and duplications were equally common findings, and the six patients with severe 
mental retardation all had duplications. One explanation may be that small deletions are easier 
to detect than duplications. It is also possible that small duplications have milder phenotypic 
consequences which reduce the chance of patient ascertainment. 
 
8.2.2.  Comparison of mapping by HR-CGH versus array-CGH (paper II) 
The recent implementation of microarray technology was expected to increase the sensitivty 
of the CGH method. Because of this, when affordable BAC-arrays became available from the 
Norwegian Microarray Consortium, all 76 HR-CGH-positive samples in paper II were re-
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examined by 1 Mb array-CGH analysis. This was done for deletion and duplication fine-
mapping, and thus more precise genotype-phenotype information. This effort also made it 
possible to compare the mapping accuracy of genomic imbalances detected by HR-CGH and 
by 1 Mb array-CGH. In general, both deletion and duplication sizes were overestimated by 
the HR-CGH software. In three out of the 40 patients with cryptic imbalances, HR-CGH 
indicated the location of a deletion or duplication that actually missed its true position. In 
three of the 36 patients with minor but visible imbalances, the HR-CGH detection in the 
subtelomeric regions was found to be misleading (i.e. no detection or inaccurate mapping of 
subtelomeric imbalances), as shown in Figure 6 where an incomplete subtelomeric HR-CGH 
detection was observed (case 58 in paper II). 
 
 
7q
HR-CGH
Array-CGH
dup
del
 
 Fig. 6. Incomplete HR-CGH detection of a subtelomeric imbalance. The 99.5% confidence interval 
HR-CGH ratio profile together with the 1 Mb array-CGH profile of the case is shown in the figure. 
The imbalances mapped by HR-CGH analysis and array-CGH analysis are shown as green bars 
(gains) or red bars (losses) beneath an 850-band ideogram of the q-arm of chromosome 7. HR-CGH 
analysis indicated a 7q-duplication from 7q33 to 7q35, while 1 Mb array-CGH analysis showed a 
duplication [dup(7)(q35q36.1)] with a terminal deletion [del(7)(q36.2qter)]. 
Illustration by Helle Lybæk. 
 
The comparison also demonstrated that the HR-CGH software may overlook even visible 
subtelomeric imbalances. A possible explanation of this problem could be that the dynamic 
standard reference intervals used in the HR-CGH software [71] corrects for regions with 
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variable signal intensities which especially is found in the heterochromatin regions, the 
centromeres and the telomeres, which may lead to a lowered HR-CGH detection in the 
subtelomeric regions. Based on our mapping results, additional specific subtelomere 
screening should be applied (e.g. by FISH) for improved detection, if using HR-CGH analysis 
for genome-wide screening of chromosomal imbalances, as is also found by others [73,91]. 
The mapping results demonstrated an improved performance of 1 Mb array-CGH compared 
to HR-CGH. 
 
It should also be noted that 1 Mb array-CGH analysis of the three samples with a HR-CGH-
detected cryptic imbalance in paper I which were not included in paper II (cases 1, 4 and 5), 
showed that the HR-CGH findings in the cases 4 and 5 were false-positives. This was 
unexpected since both HR-CGH findings were verified by either FISH-analysis (case 4) or by 
re-examination of G-banded high quality chromosomes (case 5). This emphasises the 
importance of critical interpretation when additional methods are applied for verification of 
CGH findings, and that results obtained on both G-banded karyotyping and FISH-analysis 
may lead to a false verification of a CGH finding. The 1 Mb array-CGH identification of 
false-positive HR-CGH findings confirms an improved performance of the array-CGH 
method. 
 
8.2.3. Detection of cryptic imbalances by 1 Mb array-CGH (paper II) 
For examination of the clinical usefulness of 1 Mb array-CGH analysis in the remaining 514 
patients with normal findings on both G-banded karyotyping and HR-CGH analysis, a subset 
of 20 patients with phenotypes highly suggestive of a genomic imbalance was selected. The 
results are shown in Table 4.  
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Table 4. Detection of cryptic chromosomal imbalances in patients with mental retardation by 
array-CGH only   All patients had normal findings on G-banded karyotyping and HR-CGH analysis. 
Abnormal findings 
Study Number of cases 
Total number (%) Interstitial imbal. de novo events 
Paper II 20 4 (20,0) 4 3 
 
Four new findings were made: three deletions (size range 3,1-3,3 Mb) and one duplication 
(size 8,7 Mb), all being interstitial (Table 4). The results were verified by array-CGH analysis 
done on a commercial 1 Mb BAC-array (CytoChip). Our results demonstrated a 1 Mb array-
CGH detection-rate of cryptic imbalances on 20% (Table 4). However, the sample is too 
small to conclude if this high detection rate is a chance finding or due to skilled patient 
selection. The results though indicated an improved detection capacity of cryptic imbalances 
by 1 Mb array-CGH compared to HR-CGH. 
The diagnostic potential of 1 Mb array-CGH analysis was illustrated on a larger sample 
of patients when combining data from five different European studies [77-81] including 332 
patients, which gave a 1 Mb array-CGH diagnostic detection rate of 8,4% [77]. This indicated 
only a slightly improved diagnostic yield of the 1 Mb array-CGH method as compared to the 
HR-CGH method (i.e. 7,2%). But it is important to keep in mind, that the yield of different 
diagnostic approaches is dependent on patient ascertainment. Also, in the five European 
studies summarised above, the 1 Mb array-CGH diagnostic detection rates varied from 8% 
[77] to 16% [78]. Of note, 34% of the patients in these studies had been pre-screened for 
subtelomeric imbalances, and elimination of a similar fraction of patients with subtelomeric 
findings from our cohort would have reduced our diagnostic HR-CGH detection rate to 6,7% 
(paper II).  
 
The largest cohort of patients who have been screened for genomic imbalances by array-CGH  
 51
analysis includes 8789 individuals with a variety of developmental problems [93]. Most of 
them had normal findings on initial chromosome- and DNA analyses. By the use of an array 
with a lower resolution than 1 Mb but targeted against chromosomal regions of known 
clinical relevance, a diagnostic yield of 6,9% was found [93]. Interesting, full coverage BAC 
array-CGH analysis (~100 kb resolution) of 100 patients with normal findings on both G-
banded karyotyping and MLPA subtelomere screening gave a diagnostic pick-up rate of 10% 
[85]. Thus an increase in analysis resolution does not necessarily result in a similar fold 
increase in diagnostic yield. At least not when using BAC-arrays.  
Our findings of a higher detection capacity of cryptic imbalances and an improved 
mapping accuracy demonstrated an improved diagnostic utility of the array-CGH method 
when compared to the HR-CGH method. 
 
8.2.4.  Detection of occult mosaicisms by CGH (papers II and IV) 
Unlike meiotic non-disjunctions, mitotic non-disjunctions are rarely observed in humans with 
the exception of mosaicism for trisomy 8, 9 or 20 [18,34,94]. In the papers II and IV, we 
describe five occult chromosomal mosaicisms that were detected by CGH (both HR-CGH and 
array-CGH), despite normal findings on G-banded karyotyping. The results are shown in 
Table 5. 
 
Table 5. Detection of occult chromosomal mosaicisms by both HR-CGH and array-CGH 
All cases had normal findings on G-banded karyotyping.  
Study Abnormal
cases 
Cases with 
mosaicism 
Cases with 
mosaicism in % 
Percentage of 
mosaicisma 
Type of chromosomal 
abnormality 
Paper II 40 of 554 4 of 40 10,0 15,0 – 36,0 Three trisomy 9 
One trisomy 14 
Paper IV 1 of 1 1 of 1  15,0 Combined tetraploidy 8+18 
aDetermined by interphase FISH analysis of 100 nuclei (paper II) and 200 nuclei (paper IV). 
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The CGH-detection of chromosomal mosaicism in our cohort of 554 patients was 0,7%, and 
accounted for 10% of the cryptic findings made (Table 5, paper II). These results 
demonstrated the strength of the CGH methods in detecting mosaicisms which may be 
overlooked by G-banded karyotyping when a small number of metaphases is analysed.  
Also interesting, recent studies have shown that phytohemagglutinin (PHA)-stimulation  
during culturing of blood leukocytes may lead to a selection against cells in a mosaic state 
[35,77]. This possible bias is avoided when analysing unstimulated leukocyte DNA by the 
CGH-methods, which ensures a more precise examination of the “true chromosomal content” 
in the patient. 
The importance of this latter precaution was illustrated in paper IV, where a mosaic 
combined tetraploidy of chromosomes 8 and 18 was detected by both HR-CGH and 1 Mb 
array-CGH in blood DNA from a newborn child with markedly dysmorphic features, 
malformations and developmental delay, despite normal findings on G-banded karyotyping 
(Table 5, paper IV). Of note, in contrast to mosaic trisomies, the finding of mosaic whole-
chromosome tetrasomy is without precedence in patients with mental retardation. Thus, our 
finding of a mosaic combined tetrasomy of two chromosomes is very unique. The double 
tetrasomy was caused by mitotic malsegregation of all four chromatids of both chromosome 
pairs, indirecty suggesting that a mechanism for tetraploidy correction involving pairing of 
homologues, which could be important for genome maintenance, may be present in normal 
cells. Interestingly, interphase FISH analysis of fibroblasts at age 4 months and of a buccal 
smear at age 14 months did no longer detect double tetrasomic cells. Also, CGH- and 
interphase FISH analyses of a new blood sample at age 20 months only displayed normal 
findings, indicating an early selection against the tetrasomic cells in the bone marrow.  
The reason for this unique tetraploidy finding is either a very rare chromosomal 
aberration, or that somatic malsegregation of chromosomes is a more common cause of 
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abnormal development than previously appreciated but is not found due to negative selection 
against such cells during embryonic development and during culturing of blood cells for 
routine karyotyping. We may have been fortunate to observe this event because we performed 
CGH on “unbiased” (unstimulated) leukocyte DNA from a newborn. A mosaicism grade as 
low as 8% has been detected by 1 Mb array-CGH analysis [77], again showing the important 
capacity of the CGH methods in detecting this type of chromosomal abnormality. 
 
8.2.5.  Genotype-phenotype correlation of gene dose alterations (papers III 
and V) 
The combination of several cytogenetic methods made it possible to identify candidate genes 
that might explain phenotypic features in two different families with mentally retarded 
individuals (papers III and V). In addition, the studies showed that such a combination of 
methods may be crucial for a correct characterisation of the chromosomal abnormalities being 
present in the patient. 
 
In paper III, G-banded karyotyping of a six-year-old boy with spherocytosis and mild mental 
retardation identified a paracentric inversion on chromosome 14. As expected, based on the 
patients’ phenotype of spherocytosis [95], BAC-FISH analysis against the beta-spectrin gene 
SPTB showed a deletion. But quite unexpectedly, the deletion was located outside the BAC-
FISH mapped telomeric inversion breakpoint. Oligo array-CGH analysis located the deletion 
to be ~1,6 Mb distal of the inversion breakpoint, spanning ~2,1 Mb, as summarised in Figure 
7.  The deletion contained 16 annotated genes, including SPTB causing spherocytosis, and 
PLEKHG3, a guanide nucleotide exchange factor for Rho GTPases. Rho GTPases are key 
regulators of the actin- and microtubule cytoskeletons and their possible involvement in 
mental retardation is well known [96,97]. For this reason, and because PLEKHG3 is highly  
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expressed in the brain, it is a possible candidate gene for causing the mild mental retardation. 
 
 
q21.1 q21.3 q23.1 q23.3q21.2 q22.1 q22.3 q23.2q22.2
deletioninversion
Fig.7. A ~2,1 Mb deletion located ~1,6 Mb distal to a 14q21.1q23.2 paracentric inversion. 
A schematic figure showing the positions of the paracentric inversion and downstream deletion on 
chromosome 14. An 850-band ideogram of chromosome 14 covering the region from 37 Mb to 67 Mb 
from 14pter is used for the illustration. 
Illustration by Helle Lybæk. 
 
Beside the patient, six other relatives, through three generations, were also known to have 
spherocytosis and a least two of them also had severe learning difficulties. Analysis of these 
two latter individuals gave the same chromosomal findings as identified in the proband. Due 
to limited access of samples from additional family members, we were not able to establish if 
the deletion in the family arose independently of the familiar inversion or as part of a single 
meiotic event. 
The recognizable phenotype of spherocytosis and the combination of several cytogenetic 
methods was crucial for the complete characterisation of the patient. Our results demonstrated 
that inversions can be associated with microdeletions close to but not including one of the 
inversion breakpoints, and that one should look for causative genes for a given phenotype not 
only in the breakpoint region of a de novo inversion or translocation – the real cause may be a 
de novo rearrangement nearby - or even elsewhere in the genome.  
 
In paper V, a 2 ½-year-old girl with onset of puberty before age 5 months, malformations and 
severe mental retardation was examined. An 8,9 Mb subterminal 19p13 duplication was 
detected by 1 Mb array-CGH, despite normal findings on G-banded karyotyping and 
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HR-CGH. Based on the phenotype of precocious puberty, we initially assumed that the 
duplication contained the kisspeptin receptor gene GPR54, known to stimulate induction of 
puberty [98,99]. However, mapping by high-resolution array-CGH excluded this possibility. 
Of note, the duplication proved to be difficult to detect in some of the array-CGH software at 
standard settings, even with a good data quality, making manual adjustments necessary for the 
detection. Measuring of the global gene expression in skin fibroblasts from the patient did not 
give leads for the hormonal disturbance or the mental impairment, illustrating that severe 
mental retardation and malformation can occur with only subtle changes in gene expression. 
The proband´s mother was, unexpectedly, showed to have a between-arm insertion of the 
duplicated segment that resembled a pericentric inversion. The same balanced insertion in 
several other family members, including one who had lost a daughter with severe mental 
retardation and puberty from age 10. Another carrier of the insertion, a maternal uncle, had 
also severe mental retardation, and we initially ascribed his phenotype to a presumed cryptic 
chromosome 19 imbalance caused by the 19p-into19q insertion. Instead, most unexpectedly, a 
novel 3,9 Mb deletion of 2q23.3-2q24.1 was found. The deletion contained seven annotated 
genes, among them the formin-like 2 gene FMNL2, and NR4A2, a member of the steroid-
thyroid hormone and retinoid receptor superfamily. FMNL2 has similarity to genes involved 
in Rho-dependent signal transduction [100], and as mentioned above, the involvement of 
Rho-dependent GTPases in mental retardation is well known [96,97]. NR4A2, is a 
transcription factor essential for the differentiation of dopaminergic neurons in substantia 
nigra, and mutations of the gene have been linked to familial parkinsonism [101]. Thus, 
FMNL2 and NR4A2 are likely candidate genes for causing the severe mental impairment in 
this individual. The presence of a 2q23q24 microdeletion syndrome has been suggested based 
on an overview of nine patients with deletions that included 2q23.3-2q24.1 [102]. The 
phenotypes, as well as the deletion sizes, are quite variable, but epilepsy and mental 
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retardation are recurrent features, as seen in this individual. For this reason, we proposed that 
the 3,9 Mb region may be critical for this suggested syndrome. 
During the examination of this family several unexpected results were found, and the 
study showed how challenging it may be to determine phenotype-genotype correlations, even 
in patients with recognizable phenotypes. Our results demonstrated that between-arm 
insertions are high-risk chromosomal rearrangements that can easily be misinterpreted as 
pericentric inversions, and that duplications can be difficult to detect, even by array-based 
copy number analyses. We were not able to determine a cause for the extreme precocious 
puberty in one individual, and this patient underscores the need for careful mapping of 
chromosomal aberrations before making assumptions about genotype-phenotype correlations. 
Furthermore, the study reminded us that the etiology of severe mental retardation is not 
necessarily the same in closely related individuals, and that array-CGH is very useful for 
detecting alternate explanations for mental retardation phenotypes in the same family.  
 
8.3. The challenge of interpreting detected chromosomal 
abnormalities 
The use of 1 Mb array-CGH analysis for genome-wide screening of chromosomal imbalances 
in phenotypic normal humans lead to the discovery of extensive genomic rearrangements  
ranging in size from kilobases to megabases, which were not detectable by high-resolution G-
banded karyotyping [103,104]. These normally occuring genomic variants have been called 
copy number variations (CNVs) or polymorphisms [105]. For measuring the extent of CNVs 
in the human genome, a recent study examined 270 normal individuals by tiling-BAC array-
CGH analysis and high-resolution SNP-based DNA copy number analysis [106]. A total of 
1447 CNVs were identified, covering ~12% (360 Mb) of the human genome [106]. The 
median sizes of the CNVs were 228 kb (tiling BAC-array) and 81 kb (SNP-array), and the 
 57
mean sizes were 341 kb and 206 kb, respectively. Very interestingly, the CNVs included 
hundreds of genes in deletions, duplications, insertions and complex multi-site variants in 
addition to disease loci, functional elements and segmental duplications/LCRs [106]. This 
indicates, that although the CNVs do not have (major) phenotypic consequences themselves 
(i.e. as they were detected in normal individuals), they can predispose for genomic 
rearrangements which in turn can result in a clinical phenotype, as described by others 
[24,25,27,28,105,107-109]. 
The presence of CNVs in the human genome complicates the clinical interpretation of 
genomic imbalances detected in phenotypically abnormal individuals, since a finding of an 
imbalance does not automatically indicate a pathogenic effect. If the detected imbalance in a 
patient involves a known deletion/duplication syndrome, or if the imbalance has occurred de 
novo in the patient, and especially if it contains genes with effects compatible with the clinical 
findings of the patient, then the finding is considered as pathogenic. If the imbalance is 
familial but previously unclassified, then it is difficult to determine its phenotypic 
consequence. 
 
The full understanding of the function and significance of CNVs associated with mental 
impairment is still to be solved. But as the copy number variation databases expand, as the 
Database of Genomic Variants (DGV; http://projects.tcag.ca/variation/), and genomic gains 
and losses are better associated with specific phenotypes as in the Database of Chromosomal 
Imbalance and Phenotype in Humans using Ensembl Resources (DECIPHER; 
https://decipher.sanger.ac.uk), clinical interpretation will be more reliable by comparisons of 
patient findings with CNVs in such databases. 
Also, as the genotype-phenotype databases, such as DECIPHER, expand, it will be easier 
to determine the genotype-phenotype correlations in the patients. However, since many of the 
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(non-) published rapports on patients are never reported to these databases, a lot of useful 
information is missing in the public domain. As a consequence of this, a new genotype-
phenotype correlation-tool has recently been developed, in which biomedical concepts (e.g. 
microcephaly) are mapped onto the human genome at a cytogenetic band level by mining 
literature (i.e. MEDLINE abstracts) on chromosomal aberrations [110,111]. 
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9. Concluding remarks 
Mapping of genomic imbalances with distinct phenotypes may be useful not only for 
evaluation of the clinical importance of a de novo imbalance, but also for narrowing down 
regions of particular interest when searching for genes whose dosage is critical for normal 
development. 
 
In this study, we have reported the usefulness of HR-CGH and array-CGH as screening 
methods for cryptic chromosomal imbalances in patients with mental retardation. The finding 
of a unique mosaic combined tetraploidy for chromosomes 8 and 18 by CGH in newborn 
blood DNA may indicate that somatic malsegregation of chromosomes is a more common 
cause of abnormal development than previously appreciated. The bias introduced by cell 
culturing is avoided by using CGH as the screening method. 
 
In a study of 590 patients, the HR-CGH diagnostic detection rate of cryptic imbalances was 
7,2 %. Of note, the findings were mainly interstitial and 90% were de novo. An improved 
diagnostic utility was demonstrated when 1 Mb array-CGH was applied on HR-CGH positive 
samples. In 20 patients with normal HR-CGH findings, the 1 Mb array-CGH diagnostic 
detection rate of cryptic imbalances was 20%. Evidently, the more recent array-CGH method 
is an even better diagnostic screening tool than HR-CGH in patients with mental retardation.  
 
Detailed molecular cytogenetic studies of selected cases made it possible to find candidate 
genes that may be important for normal brain development and function.  
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10.  Future perspectives 
During the last few years, commercially high-resolution oligo-arrays have been developed 
and become available in an impressive rate. And, maybe more important, the costs of these 
arrays have dropped markedly, making them more affordable for more laboratories that now 
get the opportunity of extensive analysis for submicroscopic chromosomal abnormalities. 
Also many array-systems have become highly automated which enable analysis of many 
patients in a short time period. High-resolution analyses of a large number of patients with 
mental retardation will enhance the likelihood of detecting dosage sensitive single-genes (e.g. 
“knock-out patients” or “knock-in patients”), or chromosome-regions, which are crucial for 
normal brain development and function. Also, high throughput of such analyses will provide 
more knowledge of the occurrence and function of the CNVs. However, it is crucial that data 
obtained worldwide on patients with mental retardation are reported to- and collected in 
public accessible databases for a larger collection of genotypic-phenotypic correlations in this 
patient group, which in turn will facilitate the interpretation of genomic findings made. 
Today, there are several such databases, some examples are DECIPHER (Database of 
Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources; 
https://decipher.sanger.ac.uk/), ECARUCA (European Cytogeneticists Association Register 
of Unbalanced Chromosome Aberrations; http://ecaruca.net), and DGV (Database of Genome 
variation; http://projects.tcag.ca/variation/). 
   
It is realistic to hope in the years to come that the combination of high-resolution detection of 
submicroscopic abnormalities with more knowledge on the phenotypic consequences of 
deletions, duplications and chromosomal rearrangements in patients with mental retardation, 
will result in substantionally more patients – and their relatives – getting an explanation of the 
causes of their impairment. 
 63
  
 
 
 
 
 
 
 
 
 
 64
11. References 
1. Gustavson KH, Holmgren G, Blomquist HK: Chromosomal aberrations in mildly 
mentally retarded children in a northern Swedish county. Upsala journal of medical 
sciences 1987; 44: 165-8. 
2. Roeleveld N, Zielhuis GA, Gabreels F: The prevalence of mental retardation: a critical 
review of recent literature. Developmental medicine and child neurology 1997; 39(2): 
125-32. 
3. Stromme P, Valvatne K: Mental retardation in Norway: prevalence and sub-
classification in a cohort of 30037 children born between 1980 and 1985. Acta 
paediatrica (Oslo, Norway 1998; 87(3): 291-6. 
4. Larson SA, Lakin KC, Anderson L, Kwak N, Lee JH, Anderson D: Prevalence of 
mental retardation and developmental disabilities: estimates from the 1994/1995 
National Health Interview Survey Disability Supplements. Am J Ment Retard 2001; 
106(3): 231-52. 
5. Zechner U, Wilda M, Kehrer-Sawatzki H, Vogel W, Fundele R, Hameister H: A high 
density of X-linked genes for general cognitive ability: a run-away process shaping 
human evolution? Trends Genet 2001; 17(12): 697-701. 
6. Flint J, Knight S: The use of telomere probes to investigate submicroscopic 
rearrangements associated with mental retardation. Curr Opin Genet Dev 2003; 13(3): 
310-6. 
7. Knight SJ, Regan R, Nicod A, Horsley SW, Kearney L, Homfray T, Winter RM, 
Bolton P, Flint J: Subtle chromosomal rearrangements in children with unexplained 
mental retardation. Lancet 1999; 354(9191): 1676-81. 
8. Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, Zenker M, Huffmeier U, 
Thiel C, Ruschendorf F and others: Diagnostic yield of various genetic approaches in 
patients with unexplained developmental delay or mental retardation. American 
journal of medical genetics 2006; 140(19): 2063-74. 
9. Lenhard W, Breitenbach E, Ebert H, Schindelhauer-Deutscher HJ, Henn W: 
Psychological benefit of diagnostic certainty for mothers of children with disabilities: 
lessons from Down syndrome. Am J Med Genet A 2005; 133A(2): 170-5. 
10. American Psychiatric Association. Diagnostic and statistical manual of mental 
retardation (4th ed.). 1987. Washington, DC. 
 
 65
11. World Heath Organization. International Statistical Classification of Diseases and 
Related Health Problems (10th ed.). 2007. Geneva. 
12. Luckasson R, Borthwick-Duffy S, Buntinx WH, Coulter DL, Craig EM, Reeve A, 
Schalock RL, Snell ME, Spitalnik DM, Spreat S and others. Mental retardation: 
Definition, classification, and systems of supports (10th ed.). 2002.  Washington, DC. 
American Association on Mental Retardation. 
13. Bernsen AH: Severe mental retardation among children in the county of Arhus, 
Denmark. A community study on prevalence and provision of service. Acta Psychiatr 
Scand 1976; 54(1): 43-66. 
14. Patau K, Smith DW, Therman E, Inhorn SL, Wagner HP: Multiple congenital 
anomaly caused by an extra autosome. Lancet 1960; 1(7128): 790-3. 
15. Edwards JH, Harnden DG, Cameron AH, Crosse VM, Wolff OH: A new trisomic 
syndrome. Lancet 1960; 1(7128): 787-90. 
16. Lejeune J, Gautier M, Turpin R: Etude des chromosomes somatiques de neuf enfants 
mongoliens [Study of somatic chromosomes from 9 mongoloid children.]. C R Hebd 
Seances Acad Sci 1959; 248(11): 1721-2. 
17. Miller OJ, Therman E. Human chromosomes (4th ed.). 2001.  Springer-Verlag. 
18. Gardner RJM, Sutherland GR. Chromosome Abnormalities and Genetic Counseling 
(3rd ed.). 2004.  Oxford University press. 
19. Fiegler H, Carr P, Douglas EJ, Burford DC, Hunt S, Scott CE, Smith J, Vetrie D, 
Gorman P, Tomlinson IP and others: DNA microarrays for comparative genomic 
hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes 
Chromosomes Cancer 2003; 36(4): 361-74. 
20. Jacobs PA, Strong JA: A case of human intersexuality having a possible XXY sex-
determining mechanism. Nature 1959; 183(4657): 302-3. 
21. Jacobs PA, Baikie AG, Brown WM, Macgregor TN, Maclean N, Harnden DG: 
Evidence for the existence of the human "super female". Lancet 1959; 2(7100): 423-5. 
22. Sandberg AA, Koepf GF, Ishihara T, Hauschka TS: An XYY human male. Lancet 
1961; 2(7200): 488-9. 
23. Kleinjan DA, van Heyningen V: Long-range control of gene expression: emerging 
mechanisms and disruption in disease. Am J Hum Genet 2005; 76(1): 8-32. 
24. Inoue K, Lupski JR: Molecular mechanisms for genomic disorders. Annu Rev 
Genomics Hum Genet 2002; 3: 199-242. 
 66
25. Ji Y, Eichler EE, Schwartz S, Nicholls RD: Structure of chromosomal duplicons and 
their role in mediating human genomic disorders. Genome Res 2000; 10(5): 597-610. 
26. Stankiewicz P, Lupski JR: Genome architecture, rearrangements and genomic 
disorders. Trends Genet 2002; 18(2): 74-82. 
27. Sharp AJ, Hansen S, Selzer RR, Cheng Z, Regan R, Hurst JA, Stewart H, Price SM, 
Blair E, Hennekam RC and others: Discovery of previously unidentified genomic 
disorders from the duplication architecture of the human genome. Nat Genet 2006; 
38(9): 1038-42. 
28. Sharp AJ, Locke DP, McGrath SD, Cheng Z, Bailey JA, Vallente RU, Pertz LM, 
Clark RA, Schwartz S, Segraves R and others: Segmental duplications and copy-
number variation in the human genome. Am J Hum Genet 2005; 77(1): 78-88. 
29. Biesecker LG: The end of the beginning of chromosome ends. Am J Med Genet 2002; 
107(4): 263-6. 
30. Knight SJ, Flint J: Perfect endings: a review of subtelomeric probes and their use in 
clinical diagnosis. J Med Genet 2000; 37(6): 401-9. 
31. Rossi E, Piccini F, Zollino M, Neri G, Caselli D, Tenconi R, Castellan C, Carrozzo R, 
Danesino C, Zuffardi O and others: Cryptic telomeric rearrangements in subjects with 
mental retardation associated with dysmorphism and congenital malformations. J Med 
Genet 2001; 38(6): 417-20. 
32. de Vries BB, White SM, Knight SJ, Regan R, Homfray T, Young ID, Super M, 
McKeown C, Splitt M, Quarrell OW and others: Clinical studies on submicroscopic 
subtelomeric rearrangements: a checklist. J Med Genet 2001; 38(3): 145-50. 
33. Houge G, Boman H, Lybaek H, Ness GO, Juliusson PB: Lack of meiotic crossovers 
during oogenesis in an apparent 45,X Ullrich-Turner syndrome patient with three 
children. Am J Med Genet A 2006; 140(10): 1092-7. 
34. Karadima G, Bugge M, Nicolaidis P, Vassilopoulos D, Avramopoulos D, Grigoriadou 
M, Albrecht B, Passarge E, Anneren G, Blennow E and others: Origin of 
nondisjunction in trisomy 8 and trisomy 8 mosaicism. Eur J Hum Genet 1998; 6(5): 
432-8. 
35. Ballif BC, Rorem EA, Sundin K, Lincicum M, Gaskin S, Coppinger J, Kashork CD, 
Shaffer LG, Bejjani BA: Detection of low-level mosaicism by array CGH in routine 
diagnostic specimens. Am J Med Genet A 2006; 140(24): 2757-67. 
 
 
 67
36. Cheung SW, Shaw CA, Scott DA, Patel A, Sahoo T, Bacino CA, Pursley A, Li J, 
Erickson R, Gropman AL and others: Microarray-based CGH detects chromosomal 
mosaicism not revealed by conventional cytogenetics. Am J Med Genet A 2007; 
143A(15): 1679-86. 
37. Inlow JK, Restifo LL: Molecular and comparative genetics of mental retardation. 
Genetics 2004; 166(2): 835-81. 
38. Hayashi S, Honda S, Minaguchi M, Makita Y, Okamoto N, Kosaki R, Okuyama T, 
Imoto I, Mizutani S, Inazawa J: Construction of a high-density and high-resolution 
human chromosome X array for comparative genomic hybridization analysis. J Hum 
Genet 2007; 52(5): 397-405. 
39. Chiurazzi P, Tabolacci E, Neri G: X-linked mental retardation (XLMR): from clinical 
conditions to cloned genes. Crit Rev Clin Lab Sci 2004; 41(2): 117-58. 
40. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA: Fragile-X syndrome and 
fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 
2007; 6(1): 45-55. 
41. Kooy RF, Willemsen R, Oostra BA: Fragile X syndrome at the turn of the century. 
Mol Med Today 2000; 6(5): 193-8. 
42. Mandel JL, Chelly J: Monogenic X-linked mental retardation: is it as frequent as 
currently estimated? The paradox of the ARX (Aristaless X) mutations. Eur J Hum 
Genet 2004; 12(9): 689-93. 
43. Scriver CR: The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 2007; 
28(9): 831-45. 
44. Girirajan S, Vlangos CN, Szomju BB, Edelman E, Trevors CD, Dupuis L, Nezarati M, 
Bunyan DJ, Elsea SH: Genotype-phenotype correlation in Smith-Magenis syndrome: 
evidence that multiple genes in 17p11.2 contribute to the clinical spectrum. Genet Med 
2006; 8(7): 417-27. 
45. Slager RE, Newton TL, Vlangos CN, Finucane B, Elsea SH: Mutations in RAI1 
associated with Smith-Magenis syndrome. Nat Genet 2003; 33(4): 466-8. 
46. Kleefstra T, Brunner HG, Amiel J, Oudakker AR, Nillesen WM, Magee A, Genevieve 
D, Cormier-Daire V, van Esch H, Fryns JP and others: Loss-of-function mutations in 
euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric 
deletion syndrome. Am J Hum Genet 2006; 79(2): 370-7. 
 
 
 68
47. Cardoso C, Leventer RJ, Matsumoto N, Kuc JA, Ramocki MB, Mewborn SK, 
Dudlicek LL, May LF, Mills PL, Das S and others: The location and type of mutation 
predict malformation severity in isolated lissencephaly caused by abnormalities within 
the LIS1 gene. Hum Mol Genet 2000; 9(20): 3019-28. 
48. Wilkinson LS, Davies W, Isles AR: Genomic imprinting effects on brain development 
and function. Nat Rev Neurosci 2007; 8(11): 832-43. 
49. Davies W, Isles AR, Humby T, Wilkinson LS: What are imprinted genes doing in the 
brain? Epigenetics 2007; 2(4): 201-6. 
50. Temple IK: Imprinting in human disease with special reference to transient neonatal 
diabetes and Beckwith-Wiedemann syndrome. Endocr Dev 2007; 12: 113-23. 
51. Xu J, Chen Z: Advances in molecular cytogenetics for the evaluation of mental 
retardation. Am J Med Genet C Semin Med Genet 2003; 117C(1): 15-24. 
52. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative 
quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe 
amplification. Nucleic Acids Res 2002; 30(12): e57. 
53. Armour JA, Sismani C, Patsalis PC, Cross G: Measurement of locus copy number by 
hybridisation with amplifiable probes. Nucleic Acids Res 2000; 28(2): 605-9. 
54. Koolen DA, Nillesen WM, Versteeg MH, Merkx GF, Knoers NV, Kets M, Vermeer S, 
van Ravenswaaij CM, de Kovel CG, Brunner HG and others: Screening for 
subtelomeric rearrangements in 210 patients with unexplained mental retardation 
using multiplex ligation dependent probe amplification (MLPA). J Med Genet 2004; 
41(12): 892-9. 
55. Kousoulidou L, Parkel S, Zilina O, Palta P, Puusepp H, Remm M, Turner G, Boyle J, 
van Bokhoven H, de Brouwer A and others: Screening of 20 patients with X-linked 
mental retardation using chromosome X-specific array-MAPH. Eur J Med Genet 
2007; 50(6): 399-410. 
56. Kirchhoff M, Bisgaard AM, Bryndorf T, Gerdes T: MLPA analysis for a panel of 
syndromes with mental retardation reveals imbalances in 5.8% of patients with mental 
retardation and dysmorphic features, including duplications of the Sotos syndrome and 
Williams-Beuren syndrome regions. Eur J Med Genet 2007; 50(1): 33-42. 
57. Kriek M, White SJ, Bouma MC, Dauwerse HG, Hansson KB, Nijhuis JV, Bakker B, 
van Ommen GJ, den Dunnen JT, Breuning MH: Genomic imbalances in mental 
retardation. J Med Genet 2004; 41(4): 249-55. 
 
 69
58. Tjio JH, Levan A: The chromosome number of man. Hereditas 1956; 42 1-6. 
59. Caspersson T, Zech L, Johansson C: Differential binding of alkylating fluorochromes 
in human chromosomes. Exp Cell Res 1970; 60(3): 315-9. 
60. Seabright M: A rapid banding technique for human chromosomes. Lancet 1971; 
2(7731): 971-2. 
61. Cremer T, Lichter P, Borden J, Ward DC, Manuelidis L: Detection of chromosome 
aberrations in metaphase and interphase tumor cells by in situ hybridization using 
chromosome-specific library probes. Hum Genet 1988; 80(3): 235-46. 
62. Knight SJ, Horsley SW, Regan R, Lawrie NM, Maher EJ, Cardy DL, Flint J, Kearney 
L: Development and clinical application of an innovative fluorescence in situ 
hybridization technique which detects submicroscopic rearrangements involving 
telomeres. Eur J Hum Genet 1997; 5(1): 1-8. 
63. Pinkel D, Landegent J, Collins C, Fuscoe J, Segraves R, Lucas J, Gray J: Fluorescence 
in situ hybridization with human chromosome-specific libraries: detection of trisomy 
21 and translocations of chromosome 4. Proc Natl Acad Sci U S A 1988; 85(23): 
9138-42. 
64. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, 
Ning Y, Ledbetter DH, Bar-Am I, Soenksen D and others: Multicolor spectral 
karyotyping of human chromosomes. Science 1996; 273(5274): 494-7. 
65. Speicher MR, Gwyn Ballard S, Ward DC: Karyotyping human chromosomes by 
combinatorial multi-fluor FISH. Nat Genet 1996; 12(4): 368-75. 
66. Mann SM, Burkin DJ, Grin DK, Ferguson-Smith MA: A fast, novel approach for 
DNA fibre-fluorescence in situ hybridization analysis. Chromosome Res 1997; 5(2): 
145-7. 
67. Florijn RJ, Bonden LA, Vrolijk H, Wiegant J, Vaandrager JW, Baas F, den Dunnen 
JT, Tanke HJ, van Ommen GJ, Raap AK: High-resolution DNA Fiber-FISH for 
genomic DNA mapping and colour bar-coding of large genes. Hum Mol Genet 1995; 
4(5): 831-6. 
68. Raap AK, Florijn RJ, Blonden LAJ, Wiegant J, Vaandrager JW, Vrolijk H, den 
Dunnen J, Tanke HJ, van Ommen GJ: Fiber FISH as a DNA Mapping Tool. Methods 
1996; 9(1): 67-73. 
69. Lee C, Gisselsson D, Jin C, Nordgren A, Ferguson DO, Blennow E, Fletcher JA, 
Morton CC: Limitations of chromosome classification by multicolor karyotyping. Am 
J Hum Genet 2001; 68(4): 1043-7. 
 70
70. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel 
D: Comparative genomic hybridization for molecular cytogenetic analysis of solid 
tumors. Science 1992; 258(5083): 818-21. 
71. Kirchhoff M, Gerdes T, Rose H, Maahr J, Ottesen AM, Lundsteen C: Detection of 
chromosomal gains and losses in comparative genomic hybridization analysis based 
on standard reference intervals. Cytometry 1998; 31(3): 163-73. 
72. Kirchhoff M, Gerdes T, Maahr J, Rose H, Bentz M, Dohner H, Lundsteen C: 
Deletions below 10 megabasepairs are detected in comparative genomic hybridization 
by standard reference intervals. Genes Chromosomes Cancer 1999; 25(4): 410-3. 
73. Schoumans J, Nielsen K, Jeppesen I, Anderlid BM, Blennow E, Brondum-Nielsen K, 
Nordenskjold M: A comparison of different metaphase CGH methods for the 
detection of cryptic chromosome aberrations of defined size. Eur J Hum Genet 2004; 
12(6): 447-54. 
74. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, 
Chen C, Zhai Y and others: High resolution analysis of DNA copy number variation 
using comparative genomic hybridization to microarrays. Nat Genet 1998; 20(2): 207-
11. 
75. Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, 
Hindle AK, Huey B, Kimura K and others: Assembly of microarrays for genome-wide 
measurement of DNA copy number. Nat Genet 2001; 29(3): 263-4. 
76. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, 
Cremer T, Lichter P: Matrix-based comparative genomic hybridization: biochips to 
screen for genomic imbalances. Genes Chromosomes Cancer 1997; 20(4): 399-407. 
77. Menten B, Maas N, Thienpont B, Buysse K, Vandesompele J, Melotte C, de Ravel T, 
Van Vooren S, Balikova I, Backx L and others: Emerging patterns of cryptic 
chromosomal imbalance in patients with idiopathic mental retardation and multiple 
congenital anomalies: a new series of 140 patients and review of published reports. J 
Med Genet 2006; 43(8): 625-33. 
78. Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante AM, Sloos W, Otto PA, 
Kriek M, Hansson K, Krepischi-Santos AC, Fiegler H and others: Array-CGH 
detection of micro rearrangements in mentally retarded individuals: clinical 
significance of imbalances present both in affected children and normal parents. J Med 
Genet 2006; 43(2): 180-6. 
 71
79. Schoumans J, Ruivenkamp C, Holmberg E, Kyllerman M, Anderlid BM, 
Nordenskjold M: Detection of chromosomal imbalances in children with idiopathic 
mental retardation by array based comparative genomic hybridisation (array-CGH). J 
Med Genet 2005; 42(9): 699-705. 
80. Shaw-Smith C, Redon R, Rickman L, Rio M, Willatt L, Fiegler H, Firth H, Sanlaville 
D, Winter R, Colleaux L and others: Microarray based comparative genomic 
hybridisation (array-CGH) detects submicroscopic chromosomal deletions and 
duplications in patients with learning disability/mental retardation and dysmorphic 
features. J Med Genet 2004; 41(4): 241-8. 
81. Vissers LE, de Vries BB, Osoegawa K, Janssen IM, Feuth T, Choy CO, Straatman H, 
van der Vliet W, Huys EH, van Rijk A and others: Array-based comparative genomic 
hybridization for the genomewide detection of submicroscopic chromosomal 
abnormalities. Am J Hum Genet 2003; 73(6): 1261-70. 
82. Krepischi-Santos AC, Vianna-Morgante AM, Jehee FS, Passos-Bueno MR, 
Knijnenburg J, Szuhai K, Sloos W, Mazzeu JF, Kok F, Cheroki C and others: Whole-
genome array-CGH screening in undiagnosed syndromic patients: old syndromes 
revisited and new alterations. Cytogenet Genome Res 2006; 115(3-4): 254-61. 
83. Wang NJ, Liu D, Parokonny AS, Schanen NC: High-resolution molecular 
characterization of 15q11-q13 rearrangements by array comparative genomic 
hybridization (array CGH) with detection of gene dosage. Am J Hum Genet 2004; 
75(2): 267-81. 
84. Buckley PG, Mantripragada KK, Benetkiewicz M, Tapia-Paez I, Diaz De Stahl T, 
Rosenquist M, Ali H, Jarbo C, De Bustos C, Hirvela C and others: A full-coverage, 
high-resolution human chromosome 22 genomic microarray for clinical and research 
applications. Hum Mol Genet 2002; 11(25): 3221-9. 
85. de Vries BB, Pfundt R, Leisink M, Koolen DA, Vissers LE, Janssen IM, Reijmersdal 
S, Nillesen WM, Huys EH, Leeuw N and others: Diagnostic genome profiling in 
mental retardation. Am J Hum Genet 2005; 77(4): 606-16. 
86. Carvalho B, Ouwerkerk E, Meijer GA, Ylstra B: High resolution microarray 
comparative genomic hybridisation analysis using spotted oligonucleotides. J Clin 
Pathol 2004; 57(6): 644-6. 
87. Ylstra B, van den Ijssel P, Carvalho B, Brakenhoff RH, Meijer GA: BAC to the 
future! or oligonucleotides: a perspective for micro array comparative genomic 
hybridization (array CGH). Nucleic Acids Res 2006; 34(2): 445-50. 
 72
88. van Karnebeek CD, Jansweijer MC, Leenders AG, Offringa M, Hennekam RC: 
Diagnostic investigations in individuals with mental retardation: a systematic literature 
review of their usefulness. European journal of human genetics 2005; 13(1): 6-25. 
89. Baker E, Hinton L, Callen DF, Altree M, Dobbie A, Eyre HJ, Sutherland GR, 
Thompson E, Thompson P, Woollatt E and others: Study of 250 children with 
idiopathic mental retardation reveals nine cryptic and diverse subtelomeric 
chromosome anomalies. Am J Med Genet 2002; 107(4): 285-93. 
90. Riegel M, Baumer A, Jamar M, Delbecque K, Herens C, Verloes A, Schinzel A: 
Submicroscopic terminal deletions and duplications in retarded patients with 
unclassified malformation syndromes. Hum Genet 2001; 109(3): 286-94. 
91. Kirchhoff M, Pedersen S, Kjeldsen E, Rose H, Duno M, Kolvraa S, Lundsteen C: 
Prospective study comparing HR-CGH and subtelomeric FISH for investigation of 
individuals with mental retardation and dysmorphic features and an update of a study 
using only HR-CGH. Am J Med Genet A 2004; 127A(2): 111-7. 
92. Kirchhoff M, Rose H, Lundsteen C: High resolution comparative genomic 
hybridisation in clinical cytogenetics. J Med Genet 2001; 38(11): 740-4. 
93. Shaffer LG, Bejjani BA, Torchia B, Kirkpatrick S, Coppinger J, Ballif BC: The 
identification of microdeletion syndromes and other chromosome abnormalities: 
cytogenetic methods of the past, new technologies for the future. Am J Med Genet C 
Semin Med Genet 2007; 145C(4): 335-45. 
94. Micale MA, Wolff DJ, Dickerman LH, Redline R, Conroy JM, Schwartz S: 
Cytogenetic and molecular genetic characterization of trisomy 20 mosaicism in fetal 
blood and tissues. Prenat Diagn 1996; 16(10): 893-7. 
95. Fukushima Y, Byers MG, Watkins PC, Winkelmann JC, Forget BG, Shows TB: 
Assignment of the gene for beta-spectrin (SPTB) to chromosome 14q23----q24.2 by in 
situ hybridization. Cytogenet Cell Genet 1990; 53(4): 232-3. 
96. Nadif Kasri N, Van Aelst L: Rho-linked genes and neurological disorders. Pflugers 
Arch 2008; 455(5): 787-97. 
97. Newey SE, Velamoor V, Govek EE, Van Aelst L: Rho GTPases, dendritic structure, 
and mental retardation. J Neurobiol 2005; 64(1): 58-74. 
98. Semple RK, Achermann JC, Ellery J, Farooqi IS, Karet FE, Stanhope RG, O'Rahilly 
S, Aparicio SA: Two novel missense mutations in g protein-coupled receptor 54 in a 
patient with hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2005; 90(3): 
1849-55. 
 73
99. Teles MG, Bianco SD, Brito VN, Trarbach EB, Kuohung W, Xu S, Seminara SB, 
Mendonca BB, Kaiser UB, Latronico AC: A GPR54-activating mutation in a patient 
with central precocious puberty. N Engl J Med 2008; 358(7): 709-15. 
100. Katoh M, Katoh M: Identification and characterization of human FMNL1, FMNL2 
and FMNL3 genes in silico. Int J Oncol 2003; 22(5): 1161-8. 
101. Le WD, Xu P, Jankovic J, Jiang H, Appel SH, Smith RG, Vassilatis DK: Mutations in 
NR4A2 associated with familial Parkinson disease. Nat Genet 2003; 33(1): 85-9. 
102. Maas SM, Hoovers JM, van Seggelen ME, Menzel DM, Hennekam RC: Interstitial 
deletion of the long arm of chromosome 2: a clinically recognizable microdeletion 
syndrome? Clin Dysmorphol 2000; 9(1): 47-53. 
103. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee 
C: Detection of large-scale variation in the human genome. Nat Genet 2004; 36(9): 
949-51. 
104. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, 
Walker M, Chi M and others: Large-scale copy number polymorphism in the human 
genome. Science 2004; 305(5683): 525-8. 
105. Freeman JL, Perry GH, Feuk L, Redon R, McCarroll SA, Altshuler DM, Aburatani H, 
Jones KW, Tyler-Smith C, Hurles ME and others: Copy number variation: new 
insights in genome diversity. Genome Res 2006; 16(8): 949-61. 
106. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero 
MH, Carson AR, Chen W and others: Global variation in copy number in the human 
genome. Nature 2006; 444(7118): 444-54. 
107. Kriek M, White SJ, Szuhai K, Knijnenburg J, van Ommen GJ, den Dunnen JT, 
Breuning MH: Copy number variation in regions flanked (or unflanked) by duplicons 
among patients with developmental delay and/or congenital malformations; detection 
of reciprocal and partial Williams-Beuren duplications. Eur J Hum Genet 2006; 14(2): 
180-9. 
108. Sahoo T, Bacino CA, German JR, Shaw CA, Bird LM, Kimonis V, Anselm I, 
Waisbren S, Beaudet AL, Peters SU: Identification of novel deletions of 15q11q13 in 
Angelman syndrome by array-CGH: molecular characterization and genotype-
phenotype correlations. Eur J Hum Genet 2007; 15(9): 943-9. 
 
 
 
 
 74
 75
109. Giglio S, Broman KW, Matsumoto N, Calvari V, Gimelli G, Neumann T, Ohashi H, 
Voullaire L, Larizza D, Giorda R and others: Olfactory receptor-gene clusters, 
genomic-inversion polymorphisms, and common chromosome rearrangements. Am J 
Hum Genet 2001; 68(4): 874-83. 
110. Van Vooren S, Coessens B, De Moor B, Moreau Y, Vermeesch JR: Array 
comparative genomic hybridization and computational genome annotation in 
constitutional cytogenetics: suggesting candidate genes for novel submicroscopic 
chromosomal imbalance syndromes. Genet Med 2007; 9(9): 642-9. 
111. Van Vooren S, Thienpont B, Menten B, Speleman F, De Moor B, Vermeesch J, 
Moreau Y: Mapping biomedical concepts onto the human genome by mining literature 
on chromosomal aberrations. Nucleic Acids Res 2007; 35(8): 2533-43. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
